UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

  

 

 

FORM 10-Q

 

 

 

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended June 30, 2012

 

OR

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from

 

Commission File Number 000-53754

 

 

 

VYSTAR CORPORATION

(Exact Name of Registrant as Specified in its Charter)

 

 

 

Georgia   20-2027731

(State or other jurisdiction of

incorporation or organization)

 

(IRS Employer

Identification No.)

 

3235 Satellite Blvd.

Building 400, Suite 290

Duluth, GA 30096

(Address of Principal Executive Offices, Zip Code)

 

(770) 965-0383

(Registrant's telephone number including area code)

 

(Former name, former address and former fiscal year, if changed since last report)

 

 

  

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    YES    x    NO    ¨

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    YES   x      NO   ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated

filer   ¨

Accelerated filer   ¨ Non-accelerated filer   ¨

Smaller reporting

company   x

    (Do not check if a smaller reporting company)

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.)    YES   ¨     NO   x

 

As of August 6, 2012 there were 21,551,248 shares of the Registrant’s common stock, par value $0.0001 per share, outstanding.

 

 
 

 

Vystar Corporation

Form 10-Q for the Quarter Ended June 30, 2012

 

Index

 

Part I.  Financial Information
     
Item 1. Financial Statements  
  Balance Sheets at June 30, 2012 (unaudited) and December 31, 2011 3
  Statements of Operations for the Three and Six Months Ended June 30, 2012 and 2011 (unaudited) 4
  Statements of Cash Flows for the Six Months Ended June 30, 2012 and 2011 (unaudited) 5
  Notes to Financial Statements (unaudited) 6
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 14
     
Item 3. Quantitative and Qualitative Disclosures About Market Risk 19
     
Item 4. Controls and Procedures 19
     
Part II.  Other Information
     
Item 1. Legal Proceedings 20
     
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 20
     
Item 3. Defaults Upon Senior Securities 21
     
Item 4. Mine Safety Disclosures 21
     
Item 5. Other Information 21
     
Item 6. Exhibits 21

 

 

2
 

 

Part I.       FINANCIAL INFORMATION

 

ITEM 1.    Financial Statements

VYSTAR CORPORATION

BALANCE SHEETS

 

    June 30,
2012
    December 31,
2011
 
    (unaudited)        
 ASSETS                
                 
CURRENT ASSETS                
Cash   $ 386,914     $ 16,659  
Accounts receivable, net of allowance for uncollectible amount of $33,745 at June 30, 2012 and December 31, 2011, respectively     21,951       13,247  
Inventory     -       41,239  
Prepaid expenses     76,434       73,240  
Other     5,757       5,859  
TOTAL CURRENT ASSETS     491,056       150,244  
                 
PROPERTY AND EQUIPMENT, NET     668       1,113  
                 
OTHER ASSETS                
Deferred financing costs     334,891       530,297  
Patents and trademarks, net     180,853       162,688  
Other     4,421       4,421  
                 
TOTAL ASSETS   $ 1,011,889     $ 848,763  
                 
 LIABILITIES AND STOCKHOLDERS' DEFICIT                
                 
CURRENT LIABILITIES                
Accounts payable   $ 291,994     $ 428,521  
Current portion, shareholder notes payable, net of debt discount of $21,320 at June 30, 2012     577,555       -  
Accrued compensation     16,110       26,905  
Accrued expenses     76,436       124,320  
TOTAL CURRENT LIABILITIES     962,095       579,746  
                 
SHAREHOLDER NOTES PAYABLE, net of debt discount of $35,960 at December 31, 2011     -       489,040  
RELATED PARTY LINE OF CREDIT     999,875       938,750  
TOTAL LIABILITIES     1,961,970       2,007,536  
                 
STOCKHOLDERS' DEFICIT                
Preferred stock, $0.0001 par value, 15,000,000 shares authorized; none issued and outstanding     -       -  
Common stock, $0.0001 par value, 50,000,000 shares authorized; 21,520,248 and 16,407,201 shares issued and outstanding at June 30, 2012 and December 31, 2011, respectively     2,152       1,641  
Additional paid-in capital     17,978,527       16,590,829  
Deferred compensation     -       (90,000 )
Accumulated deficit     (18,930,760 )     (17,661,243 )
TOTAL STOCKHOLDERS' DEFICIT     (950,081 )     (1,158,773 )
                 
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT   $ 1,011,889     $ 848,763  

 

The accompanying notes are an integral part of these financial statements.

 

3
 

 

VYSTAR CORPORATION

STATEMENTS OF OPERATIONS

(unaudited)

  

    Three Months Ended June 30,     Six Months Ended June 30,  
    2012     2011     2012     2011  
                         
REVENUES   $ 20,419     $ 125,892     $ 144,447     $ 244,931  
                                 
COST OF REVENUES     2,800       75,075       143,483       152,955  
Gross Margin     17,619       50,817       964       91,976  
                                 
OPERATING EXPENSES                                
Sales and marketing, including non-cash share-based compensation of $11,612 and $30,893 for the three months ended June 30, 2012 and 2011, respectively and $32,607 and $124,305 for the six months ended June 30, 2012 and 2011, respectively     118,848       178,301       214,344       428,913  
General and administrative, including non-cash share-based compensation of $75,007 and $115,187 for the three months ended June 30, 2012 and 2011, respectively and $244,632 and $611,377 for the six months ended June 30, 2012 and 2011, respectively     327,927       356,307       759,182       1,146,478  
Research and development     14,642       20,844       23,075       47,203  
Total Operating Expenses     461,417       555,452       996,601       1,622,594  
                                 
LOSS FROM OPERATIONS     (443,798 )     (504,635 )     (995,637 )     (1,530,618 )
                                 
OTHER INCOME (EXPENSE)                                
Other income     -       -       5,250       -  
Interest income     216       273       300       471  
Interest expense     (140,943 )     (752,741 )     (279,430 )     (790,494 )
                                 
NET LOSS   $ (584,525 )   $ (1,257,103 )   $ (1,269,517 )   $ (2,320,641 )
                                 
Basic and Diluted Loss per Share   $ (0.03 )   $ (0.08 )   $ (0.07 )   $ (0.15 )
                                 
Basic and Diluted Weighted Average Number of Common Shares Outstanding     19,689,456       15,511,776       18,487,791       15,464,993  

  

The accompanying notes are an integral part of these financial statements.

 

4
 

 

VYSTAR CORPORATION

STATEMENTS OF CASH FLOWS

(unaudited)

 

    Six Months Ended June 30,  
    2012     2011  
CASH FLOWS FROM OPERATING ACTIVITIES                
Net loss   $ (1,269,517 )   $ (2,320,641 )
Adjustment to reconcile net loss to net cash used in operating activities                
Share-based compensation expense     289,160       735,682  
Depreciation     445       1,064  
Amortization of patents and trademarks     6,654       5,320  
Amortization of deferred financing costs     246,296       750,261  
(Increase) decrease in assets                
Accounts receivable     (8,704 )     (23,520 )
Inventory     41,239       145,034  
Prepaid expenses     (3,194 )     21,619  
Other     102       9,456  
Increase (decrease) in liabilities                
Accounts payable     (136,527 )     44,573  
Accrued compensation and expenses     (11,054 )     (179,310 )
                 
Net cash used in operating activities     (845,100 )     (810,462 )
                 
CASH FLOWS FROM INVESTING ACTIVITIES                
Cost of patents     (24,819 )     (35,549 )
                 
Net cash used in investing activities     (24,819 )     (35,549 )
                 
CASH FLOWS FROM FINANCING ACTIVITIES                
Issuance of common stock, net of costs     1,189,049       41,250  
Proceeds from related party line of credit     61,125       633,750  
Proceeds from notes payable     -       525,000  
Deferred financing costs     (10,000 )     (389,289 )
                 
Net cash provided by financing activities     1,240,174       810,711  
                 
NET (DECREASE) INCREASE IN CASH     370,255       (35,300 )
                 
CASH - BEGINNING OF PERIOD     16,659       282,625  
                 
CASH - END OF PERIOD   $ 386,914     $ 247,325  
                 
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION                
Stock purchase warrants issued in connection with line of credit and notes payable financings   $ -     $ 797,409  
 Beneficial conversion feature associated with shareholder notes payable     -       29,287  
                 
CASH PAID DURING THE PERIOD FOR                
Interest   $ 20,761     $ 1,117  

 

The accompanying notes are an integral part of these financial statements.

 

5
 

 

VYSTAR CORPORATION

NOTES TO FINANCIAL STATEMENTS

June 30, 2012 (unaudited)

 

NOTE 1- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Nature of Business

Vystar Corporation (“Vystar”, the “Company”, “we”, “us”, or “our”) is the creator and exclusive owner of the innovative technology to produce Vytex® Natural Rubber Latex ("NRL"). This technology reduces antigenic and total protein in natural rubber latex products to virtually undetectable levels in both liquid NRL and finished latex products.  Vystar has introduced Vytex NRL, its “ultra low protein” natural rubber latex, throughout the worldwide marketplace that uses NRL or latex substitutes as the latex raw material for end products.  Natural rubber latex or latex substitutes are used in an extensive range of products including balloons, textiles, footwear and clothing (threads), adhesives, foams, furniture, carpet, paints, coatings, protective equipment, sporting equipment, and, especially health care products such as condoms, surgical and exam gloves, among others. The Company produces Vytex through toll manufacturing and licensing agreements and has introduced Vytex NRL into the supply channels with targeted marketing campaigns directed to the end users as well as the manufacturers.  During 2008, the Company signed an agreement with Revertex (Malaysia) for the production of Vytex NRL with Revertex being a non-exclusive, toll manufacturer for Vystar.  In 2011, an additional non-exclusive, toll manufacturing agreement for the production of Vytex NRL was signed with Mardec Yala Company Ltd. To implement our licensing model, in March 2010 we signed a licensing agreement with Pica de Hule Natural, a division of GrupoAgroindustrialOccidente (“Occidente”), located in Guatemala, primarily for sale in the Americas.  In October 2010, we signed a second licensing agreement with KA Prevulcanized Latex (KAPVL) to manufacture and sell Vytex NRL in the SAARC region which includes India, Pakistan, Sri Lanka, Bangladesh, Bhutan and Nepal.

 

Basis of Presentation

The accompanying unaudited financial statements have been prepared in accordance with generally accepted accounting principles of the United States of America (“GAAP”) for interim financial information.  Accordingly, certain information and footnotes required by GAAP for complete financial statements may be condensed or omitted.  These interim financial statements should be read in conjunction with our audited financial statements and notes thereto included in the Company's annual report on Form 10-K for the year ended December 31, 2011, filed with the Securities and Exchange Commission ("SEC").  In the opinion of Vystar management, these financial statements contain all adjustments (which comprise only normal and recurring accruals) necessary to present fairly the financial position and results of operations as of and for the three and six month periods ended June 30, 2012 and 2011. Prior year amounts have been combined to agree with the basis of presentation.

 

Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying disclosures.  Although these estimates are based on management’s best knowledge of current events and actions the Company may undertake in the future, actual results could differ from these estimates. Examples include valuation allowances for deferred tax assets, provisions for bad debts, and fair values of share-based compensation.

 

Concentration of Credit Risk

Certain financial instruments potentially subject the Company to concentrations of credit risk.  These financial instruments consist primarily of cash and accounts receivable.  Cash held in banks in many cases exceeds the Federal Deposit Insurance Corporation, or FDIC, insurance limits.  While we monitor our cash balances on a regular basis and adjust the balances as appropriate, these balances could be impacted if the underlying financial institutions fail.  To date, we have experienced no loss or lack of access to our cash; however, we can provide no assurances that access to our cash will not be impacted by adverse conditions in the financial markets.

 

Inventory

Inventory consisting of Vytex NRL is stated at the lower of cost or market and cost is determined using the first-in, first-out (FIFO) method.

 

Loss Per Share

Because the Company reported a net loss for the six month periods ended June 30, 2012 and 2011, common stock equivalents, including stock options and warrants, were anti-dilutive; therefore, the amounts reported for basic and dilutive loss per share were the same.  Excluded from the computation of diluted loss per share were options to purchase 4,957,500 shares and 4,373,333 shares of common stock for the six months ended June 30, 2012 and 2011, respectively, as their effect would be anti-dilutive.  Warrants to purchase 10,177,774 shares and 4,360,624 shares of common stock for the six months ended June 30, 2012 and 2011, respectively, were also excluded from the computation of diluted loss per share as their effect would be anti-dilutive.

 

6
 

 

VYSTAR CORPORATION

NOTES TO FINANCIAL STATEMENTS

June 30, 2012 (unaudited)

 

 

Revenues

We derive most of our revenue from the sales of or license fees from our Vytex Natural Rubber Latex raw material to various manufacturers of rubber and rubber end products using NRL and/or their distributors.  The Company recognizes revenue when the following four criteria are met: (1) persuasive evidence of an arrangement exists; (2) shipment or delivery has occurred; (3) the price is fixed or determinable and (4) collectability is reasonably assured.    Revenue is recognized at the time product is shipped and title passes to the customer.

 

Fair Value of Financial Instruments

The Company’s financial instruments consist of cash, accounts receivable, accounts payable, accrued expenses, line of credit and shareholder notes payable.  The carrying values of all the Company’s financial instruments approximate fair value because of their short maturities. In addition to the short maturities, the carrying amounts of our line of credit and shareholder notes payable approximate fair value because the interest rates at June 30, 2012 approximate market interest rates for the respective borrowings.

 

In specific circumstances, certain assets and liabilities are reported or disclosed at fair value.  Fair value is the exit price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date in the Company's principal market for such transactions.  If there is not an established principal market, fair value is derived from the most advantageous market.

 

Valuation inputs are classified in the following hierarchy:

 

· Level 1 inputs are unadjusted quoted prices in active markets for identical assets or liabilities.
· Level 2 inputs are directly or indirectly observable valuation inputs for the asset or liability, excluding Level 1 inputs.
· Level 3 inputs are unobservable inputs for the asset or liability.

 

Highest priority is given to Level 1 inputs and the lowest priority to Level 3 inputs.  Acceptable valuation techniques include the market approach, income approach, and cost approach.  In some cases, more than one valuation technique is used.

 

Subsequent Events 

 

The Company evaluated subsequent events through the date these financial statements were issued. We are not aware of any significant events that occurred subsequent to the balance sheet date but prior to the filing of this report that would have a material impact on our financial statements.

  

NOTE 2 – LIQUIDITY AND GOING CONCERN

 

The Company's financial statements are prepared using the accrual method of accounting in accordance with accounting principles generally accepted in the United States of America and have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities in the normal course of business.  However, the Company has incurred significant losses and experienced negative cash flow since its inception.  At June 30, 2012, the Company had cash of $386,914 and a deficit in working capital of $471,039.  Further, at June 30, 2012, the accumulated deficit amounted to $18,930,760.  As a result of the Company's history of losses and financial condition, there is substantial doubt about the ability of the Company to continue as a going concern.

 

A successful transition to attaining profitable operations is dependent upon obtaining sufficient financing to fund the Company’s planned expenses and achieving a level of revenues adequate to support the Company’s cost structure.  Management plans to finance future operations through the use of cash on hand, increased revenues, and a private placement that is discussed in Note 7.  We also expect to receive proceeds from stock warrant exercises from existing shareholders. As the Company’s product continues to gain market acceptance, the Company expects sales in 2012 and beyond to continually increase.

 

There can be no assurances that the Company will be able to achieve its projected level of revenues in 2012 and beyond.  If the Company is unable to achieve its projected revenues and is not able to obtain alternate additional financing of equity or debt, the Company would need to significantly curtail or reorient its operations during 2012, which could have a material adverse effect on the Company’s ability to achieve its business objectives and as a result may require the Company to file for bankruptcy or cease operations.  The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts classified as liabilities that might be necessary should the Company be forced to take any such actions.

 

7
 

 

VYSTAR CORPORATION

NOTES TO FINANCIAL STATEMENTS

June 30, 2012 (unaudited)

 

NOTE 3 – PROPERTY AND EQUIPMENT

 

Property and equipment consists of the following at June 30, 2012 and December 31, 2011:

 

    June 30, 2012     December 31, 2011  
             
Furniture and fixtures   $ 15,347     $ 15,347  
Equipment     23,431       23,431  
      38,778       38,778  
Accumulated depreciation     (38,110 )     (37,665 )
                 
    $ 668     $ 1,113  

 

Depreciation expense for the three months ended June 30, 2012 and 2011 was $222 and $508, respectively, and for the six months ended June 30, 2012 and 2011 was $445 and $1,064, respectively.

 

NOTE 4 – PATENTS AND TRADEMARKS

 

Patents represent legal and other fees associated with the registration of patents.  The Company has three issued patents in the United States (U.S.) and three issued patents outside of the U.S. (Japan, China, and South Africa) with more than a dozen pending patent applications in the U.S. and internationally.

 

The Company has incurred legal and other fees associated with its application to the USPTO for trademark protection for “Vystar”, “Vytex”, and “Created by Nature. Recreated by Science.” during 2011 and 2010.

 

 Patents and trademarks are as follows:

 

    June 30, 2012     December 31, 2011  
             
Patents   $ 209,827     $ 185,008  
Accumulated amortization     (38,046 )     (31,392 )
      171,781       153,616  
Trademarks     9,072       9,072  
                 
    $ 180,853     $ 162,688  

 

Amortization expense for of the three months ended June 30, 2012 and 2011 was $3,402 and $2,660, respectively, and for the six months ended June 30, 2012 and 2011 was $6,654 and $5,320, respectively.

 

NOTE 5 – INCOME TAXES

 

There is no income tax benefit recorded for the losses for the three and six months ended June 30, 2012 and 2011 since management has determined that the realization of the net deferred tax asset is not assured and has created a valuation allowance for the entire amount of the net deferred tax asset.

 

8
 

 

VYSTAR CORPORATION

NOTES TO FINANCIAL STATEMENTS

June 30, 2012 (unaudited)

 

NOTE 6 – NOTES PAYABLE AND LOAN FACILITY

 

On April 29, 2011, the Company executed with CMA Investments, LLC, a Georgia limited liability company (“CMA”), a line of credit with a principal amount of up to $800,000 (the “CMA Note”). CMA is a limited liability company of which three of the directors of the Company (“CMA directors”) are the members. Pursuant to the terms of the CMA Note, the Company may draw up to a maximum principal amount of $800,000. Interest, which is computed at LIBOR plus 5.25% (5.5% at June 30, 2012), on amounts drawn and fees, will be paid by a director of the Company, to CMA. The weighted average interest rate in effect on the borrowings for the six months ended June 30, 2012 was 5.53%. Pursuant to an agreement between the Company and such affiliate, the Company will issue common stock to such affiliate with a value equal to such interest and fees paid based on the closing price of the common stock on the OTC Bulletin Board on the date of such payments. This agreement was modified during February 2012 and the Company assumed responsibility for payment of such interest and fees. The maturity date of the CMA Note is April 29, 2013.

 

Other terms of the CMA Note include:

· The CMA Note is unsecured.
· No payments of principal are due until the second anniversary of the CMA Note, at which time all outstanding principal is due and payable; and
· As compensation to the directors for providing the CMA Note, the Company issued warrants to purchase 2,600,000 shares of the Company’s common stock to the CMA Directors at $0.45 per share, which was the closing price of the Company’s stock on April 29, 2011, which vest 20% immediately and 10% upon each draw by the Company of $100,000 under the CMA Note. Because the warrants were issued and valued prior to the receipt of funds under this loan, no discount could be recorded and, accordingly, the value of the warrants was capitalized as a financing cost. The costs are being amortized on a straight line basis over the term of the CMA Note.

 

On September 14, 2011, the Company’s Board of Directors approved increasing the line of credit with CMA by $200,000 to a maximum principal amount of $1,000,000 and the Company’s Chairman and Chief Executive Officer became a member of CMA. As compensation to the CMA Directors for increasing the amount available under the CMA Note, the CMA Directors approved modifying the exercise price for the 2,600,000 compensatory stock purchase warrants previously issued to the directors from $0.45 to $0.27 per share, which was the closing price of the Company’s common stock on that date and the Company also issued warrants to purchase an additional 1,600,000 shares of the Company’s stock at $0.27 per share, which was the closing price of the Company’s common stock on September 14, 2011, which vest upon the original terms of the CMA Note. The costs incurred in the modification of the exercise price of the 2,600,000 compensatory stock purchase warrants issued on April 29, 2011 and the additional 1,600,000 warrants issued on September 14, 2011 are being amortized on a straight line basis over the remaining term of the CMA Note. Amortization of the financing costs associated with the CMA Note amounted to $89,435 and $41,208 for the three months ended June 30, 2012 and 2011, respectively, and $192,866 and $41,208 for the six months ended June 30, 2012 and 2011, respectively.

 

On March 11, 2011, the Company issued to existing shareholders of the Company an aggregate of $400,000 of convertible promissory notes (the “Notes”) together with warrants to purchase an aggregate of 160,000 shares of the Company’s common stock at $0.68 per share for two years from the date of issuance.  Such Notes are (i) unsecured, (ii) bear interest at an annual rate of ten percent (10%) per annum from January 1, 2011, and (iii) are convertible into shares of the Company’s common stock at the conversion rate of $0.68 of principal and interest for each such share.  No payments of interest or principal are payable until March 11, 2013.  The Notes may be prepaid by the Company without penalty upon 15 days prior notice to the holders. The computed value of the warrants, $23,896, is reflected as a debt discount and netted against the notes payable on the balance sheet. Additionally, in conjunction with this transaction, the Company recorded a beneficial conversion feature, given the price allocated to the Notes was less than the market price on the date of issuance, creating an intrinsic value in the conversion option. An additional $23,896 was recorded as a reduction in the Notes and an increase in paid in capital for the intrinsic value of the conversion feature.  The debt discount and beneficial conversion feature amounts are being amortized to interest expense over the life of the Notes under the effective interest method.

 

On May 31, 2011, the Company issued to existing shareholders of the Company an aggregate of $125,000 of convertible promissory notes (the “Shareholder Notes”) together with warrants to purchase an aggregate of 50,000 shares of the Company’s common stock at $0.49 per share for two years from the date of issuance. Such Shareholder Notes are (i) unsecured, (ii) bear interest at an annual rate of ten percent (10%) per annum from date of issuance, and (iii) are convertible at any time until maturity at the holder’s option into shares of the Company’s common stock at a weighted average conversion rate of $0.49 of principal and interest for each such share. No payments of interest or principal are payable until March 11, 2013. The Shareholder Notes may be prepaid by the Company without penalty upon 15 days prior notice to the holders.

 

9
 

 

VYSTAR CORPORATION

NOTES TO FINANCIAL STATEMENTS

June 30, 2012 (unaudited)

 

The computed value of the warrants issued in connection with the Shareholder Notes issued in March and May 2011, was determined to be $29,287 and is reflected as a debt discount and netted against the Shareholder Notes on the balance sheet. Additionally, in conjunction with this transaction, the Company recorded a beneficial conversion feature, given the price allocated to the Shareholder Notes was less than the market price on the date of issuance, creating an intrinsic value in the conversion option. An additional $29,287 was recorded as a reduction in the Shareholder Notes and an increase in paid in capital for the intrinsic value of the conversion feature. The debt discount and beneficial conversion feature amount are being amortized to interest expense over the life of the Shareholder Notes under the effective interest method at 15.58%.

 

The current base conversion price for the Shareholder Notes is $0.68 per share or 1,470.59 shares of the Company’s common stock for each $1,000 of principal and accrued interest. As of June 30, 2012 there had been no conversions.

 

On October 7, 2011, the Company’s Board of Directors approved modifying the exercise price for the 210,000 stock purchase warrants previously issued to existing shareholders holding convertible promissory notes to $0.27 per share, the closing price of the Company’s common stock on September 14, 2011, the date when the exercise price of warrants previously issued to the Company’s directors for providing the CMA Note were modified to $0.27 per share. The Company incurred $10,105 in interest expense for the repricing of the warrants.

 

NOTE 7 – STOCKHOLDERS’ EQUITY

 

Common Stock and Warrants

 

On December 16, 2011, the Company began a private placement offering to sell up to 4,000,000 shares of common stock. Under the terms of the offering, the Company offered to sell up to 4,000,000 shares of common stock at $0.25 per share. As of June 30, 2012 the Company had received $647,400 and issued 2,589,600 shares of common stock under the terms of the offering.

 

On May 4, 2012, the Company began a new private placement offering to sell up to 3,000,000 shares of common stock. Under the terms of the offering, the Company offered to sell up to 3,000,000 shares of common stock at $0.25 per share with one stock purchase warrant at $0.35 per share for every one common share purchased through a placement agent. As of June 30, 2012 the Company has received $475,000 and issued 1,900,000 shares of common stock and warrants to purchase an additional 1,900,000 shares of common stock. Aggregate commissions paid or issued to the Company’s placement agent were (1) $42,750 cash, (2) 133,000 shares of common stock valued at $43,890, and (3) warrants to purchase 152,000 shares of common stock at $0.35 per share, valued at $8,934. In June 2012, the Company sold 400,000 shares of common stock to an existing shareholder under the same terms as the private placement offering, receiving $100,000 and issuing 400,000 shares of common stock and warrants to purchase an additional 400,000 shares of common stock at $0.35 per share.

 

From January through February 2012, the Company issued 28,138 shares of common stock valued at $9,005 for interest for the related party CMA Note (Note 6).

 

In January 2012, the Company issued 11,209 shares of common stock valued at $2,914 as reimbursement for expenses incurred on behalf of the Company.

 

In June 2012, the Company issued 15,000 shares of common stock valued at $4,500 as reimbursement for expenses incurred on behalf of the Company.

 

The Company recorded $90,000 and $11,836 in amortization of deferred compensation expense during the six-month periods ended June 30, 2012 and 2011, respectively, related to 2011 and 2010 common stock and warrants issuances for services.

 

NOTE 8 – STOCK-BASED COMPENSATION

 

Generally accepted accounting principles requires share-based payments to employees, including grants of employee stock options, to be recognized in the income statement based on their fair values at the date of grant, net of estimated forfeitures.

 

10
 

 

VYSTAR CORPORATION

NOTES TO FINANCIAL STATEMENTS

June 30, 2012 (unaudited)

 

Options

 

The Company used the Black-Scholes option pricing model to estimate the grant-date fair value of awards granted.  No stock option grants were made in the six months ended June 30, 2012. The following assumptions were used for option awards granted during the six months ended June 30, 2011:

 

· Expected Dividend Yield – because the Company does not currently pay dividends, the expected dividend yield is zero;
· Expected Volatility in Stock Price – because trading in the Company’s stock began late in 2009 and there has been limited trading since, there was insufficient data to project the Company’s future volatility and instead the expected volatility of similar public entities (including companies engaged in the manufacture and/or distribution of medical, surgical and healthcare supplies) was considered with expected volatility of 39.17%;
· Risk-free Interest Rate – reflects the average rate on a United States Treasury bond with maturity equal to the expected term of the option, ranging from 1.32 – 2.84%; and
· Expected Life of Awards – because the Company has had minimal experience with the exercise of options or warrants for use in determining the expected life for each award, the simplified method was used to calculate an expected life based on the midpoint between the vesting date and the end of the contractual term of the stock award.

 

On March 14, 2011, the Company’s Board of Directors approved modifying the exercise price for 5,787,500 compensatory stock options and 425,282 compensatory stock purchase warrants previously issued to the Company’s employees and directors to $0.68 per share, which was the closing price of the Company’s common stock on that date.   As a result of this modification, the Company recorded non-cash stock compensation expense on March 14, 2011 of $425,000.  Additionally on March 14, 2011, the Company’s Board of Directors approved the issuance of 1,150,000 stock options to certain employees.  These new options were issued at the closing market price, $0.68, of the Company’s common stock on the date of issuance and have a 10 year term.  Vesting is immediate for 150,000 options and in equal increments on March 14, 2012, 2013 and 2014 for 1,000,000 of the options.

 

In total, the Company recorded $86,618 and $146,080 of stock-based compensation expense for the three month periods ended June 30, 2012 and 2011, respectively, and $187,239 and $735,682 for the six month periods ended June 30, 2012 and 2011, respectively, related to employee and board member stock options and warrants issued to nonemployees. As of June 30, 2012, $555,377 of unrecognized compensation expense related to non-vested share-based awards remains to be recognized over a weighted average period of approximately 1.5 years.

 

During 2004, the Board of Directors of the Company adopted a stock option plan (the “Plan”) and authorized up to 4,000,000 shares to be issued under the Plan.  In April 2009, the Company’s Board of Directors authorized an increase in the number of shares to be issued under the Plan to 10,000,000 shares, which was also approved by the Company’s shareholders, and to include the independent Board members in the plan in lieu of continuing the previous practice of granting warrants each quarter to independent board members for services.  At June 30, 2012, there were 3,512,500 shares of common stock reserved for issuance under the Plan.  The Plan is intended to permit stock options granted to employees to qualify as incentive stock options under Section 422 of the Internal Revenue Code of 1986, as amended (“Incentive Stock Options”).  All options granted under the Plan that are not intended to qualify as Incentive Stock Options are deemed to be non-qualified options.  Stock options are typically granted at an exercise price equal to the fair market value of the Company’s common stock on the date of grant, typically vest over periods up to 4 years and are typically exercisable up to 10 years.

 

The weighted-average assumptions used in the option pricing model for stock option grants were as follows for the six months ended June 30, 2011:

 

    2011  
Expected Dividend Yield     -  
Expected Volatility in Stock Price     39 %
Risk-Free Interest Rate     2.70 %
Expected Life of Stock Awards - Years     6  
Weighted Average Fair Value at Grant Date   $ 0.29  

 

11
 

 

VYSTAR CORPORATION

NOTES TO FINANCIAL STATEMENTS

June 30, 2012 (unaudited)

 

  The following table summarizes all stock option activity of the Company for the six months ended June 30, 2012:

 

    Number of     Weighted
Average
 
    Options     Exercise Price  
             
Outstanding, December 31, 2011     6,487,500     $ 0.70  
                 
Granted     -     $ -  
                 
Forfeited     -     $ -  
                 
Outstanding, June 30, 2012     6,487,500     $ 0.70  
                 
Exercisable, June 30, 2012     4,957,500     $ 0.70  

 

Warrants

 

Warrants are issued to third parties as payment for services and in conjunction with the issuance of common stock.  The fair value of each common stock warrant issued for services is estimated on the date of grant using the Black-Scholes option pricing model.  The following weighted average assumptions were used for warrants granted for the six months ended June 30:

 

    2012     2011  
Expected Dividend Yield     -       -  
Expected Volatility in Stock Price     31.57 %     39 %
Risk-Free Interest Rate     0.78 %     2.0 %
Expected Life of Awards, Years     4.5       5  

 

The following table represents the Company’s warrant activity for the six months ended June 30, 2012:

   

          Weighted Average         Weighted Average  
    Number of     Grant Date     Weighted Average   Remaining  
    Warrants     Fair Value     Exercise Price   Contractual Life (Years)  
                       
Outstanding, December 31, 2011   7,369,957         $ 0.48   7.89  
                       
Issued in private placement   2,300,000   $ 0.35   $ 0.35      
Granted   693,992   $ 0.09   $ 0.32      
Exercised   (36,000)         $ 0.26      
Expired   (150,175)         $ 0.51      
                       
Outstanding, June 30, 2012   10,177,774         $ 0.42   7.04  
                       
Exercisable, June 30, 2012   10,177,774         $ 0.42   7.04  

 

During the six months ended June 30, 2012 the Company issued 152,000 warrants for services at $0.35 per share, exercisable over 5 years from the grant date and 541,992 warrants for services at exercise prices ranging from $0.26 to $0.43 per share, exercisable over 10 years from the grant date.  All of the warrants vested immediately.  The fair value of the warrants was calculated as of the date of the grant utilizing the Black-Scholes option pricing model and assumptions as detailed above.  The total amount of the fair value was $61,586 and was recorded as noncash share-based compensation expense when vesting occurred.

 

12
 

 

VYSTAR CORPORATION

NOTES TO FINANCIAL STATEMENTS

June 30, 2012 (unaudited)

 

NOTE 8 – RELATED PARTY TRANSACTIONS

 

At December 31, 2011, the Company had accrued severance of $3,324, recorded as accrued compensation, payable to the Company’s former CFO, Glenn Smotherman. This liability was paid in full as of March 31, 2012.   

  

13
 

 

ITEM 2.  MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

GENERAL

 

Vystar Corporation (“Vystar”, the “Company”, “we”, “us”, or “our”) is the creator and exclusive owner of the innovative technology to produce Vytex® Natural Rubber Latex ("NRL"). This technology reduces antigenic protein in natural rubber latex products made with Vytex to virtually undetectable levels. The allergic reactions to untreated latex are a significant detriment affecting numerous individuals globally that use many different products made with NRL. With non-latex products growing at a rapid rate due to these allergy problems, the costs for alternative materials incurred by the manufacturers of these many different products have greatly increased. Nearly all substitute materials have been more expensive than NRL – by a factor of five in some cases. This fact has changed in the past thirteen months as NRL prices have increased by as much as 66% and continue to fluctuate in the higher priced zone.  Synthetic prices have not kept up with this increase as supply for nitrile and neoprene has exceeded demand, while crude oil prices have not kept up with the increase in NRL thus moving both below NRL itself; and, therefore well below Vytex NRL.  We have introduced Vytex NRL, our “ultra low protein” natural rubber latex, throughout the worldwide marketplace that uses NRL or latex substitutes as a component of manufactured products. We intend for Vytex NRL to become the standard source of latex and latex substitutes, not unlike a standard computer operating system on which many other applications can run. Over 9.7 million tonnes of NRL are produced globally of which just over 1.4 million tonnes are in liquid latex form. There are more than 40,000 products made from the liquid latex while the other eight million plus tonnes are used to produce tires and other hard rubber products. Natural rubber latex is used in an extensive range of products including balloons, textiles, footwear and clothing (threads), adhesives, foams, furniture, carpet, paints, coatings, protective equipment, sporting equipment, and, especially health care products such as condoms, surgical and exam gloves, catheters and other items. We have introduced Vytex NRL into the supply channels with aggressive, targeted marketing campaigns directed to the end users to create the pull-through.  This provides a competitive advantage for manufacturers utilizing Vytex NRL, ranging from those who use it as a raw material to those who are using a product that contains NRL, including manufacturers of the end products.

 

During the fourth quarter of 2009, we transitioned from the development stage to the operating stage.  This resulted from our completion of substantially all the activities associated with the developmental stage of our business and we are now involved in expanding our operations, particularly increasing market acceptance and sales of Vytex.  We are marketing to multiple industries concurrently, targeting regulated (condoms, surgical and exam gloves) and non-regulated product (foam and non-medical and non-food packaging adhesive) categories to balance the lengthier sales cycles inherent in medical devices.  A manufacturer’s conversion from their standard latex or synthetic raw material to Vytex NRL can be a protracted process, ranging from twelve to eighteen months to complete the sales cycle due to the multiple steps required.  The sales cycle generally starts with a laboratory analysis of Vytex NRL whereby physical properties and protein levels of the finished goods are tested by potential customers to ensure it meets the required specifications and then progresses to a full production run on the manufacturer’s equipment.  A manufacturer’s decision to convert to Vytex NRL is impacted by many functional areas including research and development, manufacturing, sales, marketing, purchasing and finance.   Each of these areas has a significantly different decision-making role per company thus the large difference in the sales cycle.  If the product is regulated and requires regulatory clearances or approvals prior to commercialization, the sales cycle could be extended by another nine to twelve months for testing, filing and agency review.  By diversifying the target product categories we believe this balanced approach will reduce our exposure to individual market fluctuations and increase our aggregate revenues.

 

Critical Accounting Policies and Estimates

 

Our discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. As such, we are required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. By their nature, these estimates and judgments are subject to an inherent degree of uncertainty. Our management reviews its estimates on an on-going basis. We base our estimates and assumptions on historical experience, knowledge of current conditions and our understanding of what we believe to be reasonable that might occur in the future considering available information. Actual results may differ from these estimates, and material effects on our operating results and financial position may result.   Note 1, "Summary of Significant Accounting Policies" of this Form 10-Q and in the Notes to Financial Statements in the Company's 2011 Form 10-K describes the significant accounting policies and methods used in the preparation of the Company's financial statements .

 

14
 

 

RESULTS OF OPERATIONS

 

Comparison of the Three Months Ended June 30, 2012 with the Three Months Ended June 30, 2011

 

Revenues

 

Revenues for the three months ended June 30, 2012 and 2011 were $20,419 and $125,892, respectively. During the quarter ended June 30, 2012, all of our sales were under our licensing agreement with Pica de Hule Natural, generating a gross margin of 86.3% . This was not the case in the three months ended June 30, 2011 when the Company generated a gross margin of 40.4%.

 

Operating Expenses

 

    Three Months Ended              
    June 30,     $     %  
    2012     2011     Change     Change  
OPERATING EXPENSES:                                
Sales and marketing   $ 118,848     $ 178,301     $ (59,453 )     -33.3 %
General and administrative     327,927       356,307       (28,380 )     -8.0 %
Research and development     14,642       20,844       (6,202 )     -29.8 %
    $ 461,417     $ 555,452     $ (94,035 )     -16.9 %

 

Our operating expenses were $461,417 and $555,452 for the three months ended June 30, 2012 and 2011, respectively, for a decrease of $94,035 or 16.9%.  The decrease in total operating expenses was primarily comprised of a decrease in non-cash stock-based compensation expense of $59,044, a decrease in salary expense of $72,294, and increases in investor relations, legal and professional fees aggregating $31,892.

 

For the three months ended June 30, 2012 and 2011, sales and marketing expenses were $118,848 and $178,301, respectively.  The decrease of $59,453 is primarily due to the departure of the Company’s former Executive Vice President of Sales and Business development in 2011.   Sales and marketing expenses consist primarily of compensation and support costs for sales and marketing personnel, professional services, promotional, marketing and related activities.

 

For the three months ended June 30, 2012 and 2011, general and administrative expenses were $327,927 and $356,307, respectively.  The decrease of $28,380 is primarily comprised of decreases in non-cash stock-based compensation costs of $39,763 and in salary expense of $36,755 offset by increases totaling approximately $50,819 in investor relations, legal and professional fees.  The decreased compensation expense resulted primarily from the resignation during the previous year of the Company’s Chief Financial Officer. General and administrative expenses consist primarily of compensation and support costs for management and administrative staff, and for other general and administrative costs, including professional fees related to accounting, finance, and legal services as well as other operating expenses.

 

Included in our operating expenses for the three months ended June 30, 2012 was $14,642 for research and development expenses compared to $20,844 for the three months ended June 30, 2011, a decrease of $6,202.   The decrease is primarily due to reducing costs during 2012.   Research and development expenses consist primarily of compensation for employees and contractors engaged in internal research and product development activities, laboratory operations, and related expenses.

 

Other Income (Expense)

 

Other income for the three months ended June 30, 2012, consisted of $216 of interest income on cash deposits net of interest expense of $140,943, The interest expense includes amortization of financing related costs of $105,099, $20,445 incurred in connection with the shareholder notes payable and the beneficial conversion features, interest on the notes payable of $13,901 and miscellaneous interest of $1,498.   The interest expense for the three months ended June 30, 2011 includes interest on the notes payable of $11,375, interest on the related party line of credit of $3,305, amortization of financing costs of $736,944, and miscellaneous interest of $1,117.

 

Net Loss

 

Net loss was $584,525 and $1,257,103 for the three months ended June 30, 2012 and 2011, respectively, a decrease of $672,578 in the net loss.

 

15
 

 

  Comparison of the Six Months Ended June 30, 2012 with the Six Months Ended June 30, 2010

 

Revenues

 

Revenues for the six months ended June 30, 2012 and 2011 were $144,447 and $244,931, respectively.     During the six months ended June 30, 2012, the majority of our sales were under our licensing agreement with Pica de Hule Natural. Those sales that were not were sold at a loss due to price reductions in the latex market after the production process was begun, resulting in a gross margin of 0.67% . This was not the case in the six months ended June 30, 2011 when the Company generated a gross margin of 37.6%.

 

Operating Expenses

 

    Six Months Ended              
    June 30,     $     %  
    2012     2011     Change     Change  
OPERATING EXPENSES:                                
Sales and marketing   $ 214,344     $ 428,913     $ (214,569 )     -50.0 %
General and administrative     759,182       1,146,478       (387,629 )     -33.8 %
Research and development     23,075       47,203       (24,128 )     -51.1 %
    $ 996,601     $ 1,622,594     $ (625,993 )     -38.6 %

 

Our operating expenses were $996,601 and $1,622,594 for the six months ended June 30, 2012 and 2011, respectively, for a decrease of $625,993 or 38.6%.  The decrease in total operating expenses were primarily comprised of decreases in non-cash stock-based compensation expense of $536,188 and salaries of $147,309 offset by increases in legal and professional fees aggregating $58,362.

 

For the six months ended June 30, 2012 and 2011, sales and marketing expenses were $214,344 and $428,913, respectively.  The decrease of $214,569 is primarily due to decreases in non-cash stock-based compensation of $91,698 and in salaries and benefits due to the departure of the Company’s former Executive Vice President of Sales and Business development on March 31, 2011.   Sales and marketing expenses consist primarily of compensation and support costs for sales and marketing personnel, professional services, promotional, marketing and related activities.

 

For the six months ended June 30, 2012 and 2011, general and administrative expenses were $759,182 and $1,146,478, respectively.  The decrease of $387,629 is primarily due to decreases in non-cash stock-based compensation of $366,327 and salaries of $89,195 partially offset by increases in investor relations, legal and professional fees of $92,522.   The decreased compensation expense resulted from the resignation during August 2011 of the Company’s Chief Financial Officer and also by Company officers receiving a portion of their salaries in stock options rather than cash payments during the first four months of 2012. General and administrative expenses consist primarily of compensation and support costs for management and administrative staff, and for other general and administrative costs, including professional fees related to accounting, finance, and legal services as well as other operating expenses.

 

Included in our operating expenses for the six months ended June 30, 2012 was $23,075 for research and development expenses compared to $47,203 for the six months ended June 30, 2011, a decrease of $24,128.   The decrease is primarily due to reducing costs during 2012.    Research and development expenses consist primarily of compensation for employees and contractors engaged in internal research and product development activities, laboratory operations, and related expenses.

 

Other Income (Expense)

 

Other income for the six months ended June 30, 2012, consisted of $5,250 of other income, $300 of interest income on cash deposits net of interest expense of $279,430.   The interest expense includes amortization of financing related costs of $208,531, $40,890 incurred in connection with the shareholder notes payable and the beneficial conversion features, interest on the notes payable of $27,732 and miscellaneous interest of $2,277. This compares to $471 of interest income and $790,494 of interest expense for the six months ended June 30, 2011. The interest expense includes interest on the notes payable of $21,375, interest on the related party line of credit of $3,305, amortization of financing costs of $763,919, and miscellaneous interest of $1,895.

 

Net Loss

 

Net loss was $1,269,517 and $2,320,641 for the six months ended June 30, 2012 and 2011, respectively, a decrease of $1,051,124 in the net loss.

 

16
 

 

  LIQUIDITY AND CAPITAL RESOURCES

 

As of June 30, 2012, we had current assets of $491,056, including $386,914 in cash, and $962,095 of current liabilities, or negative working capital of $471,039.  We use working capital to finance our ongoing operations and since those operations do not currently cover all of our operating costs, managing working capital is essential to our Company’s future success.  As a result of the Company's history of losses and financial condition, there is substantial doubt about the ability of the Company to continue as a going concern.

 

A successful transition to attaining profitable operations is dependent upon obtaining sufficient financing to fund the Company’s planned expenses and achieving a level of revenues adequate to support the Company’s cost structure.  Management plans to finance future operations through the use of cash on hand, increased revenues, and the on-going private placement. We also expect to receive proceeds from stock warrant exercises from existing shareholders.  As the Company’s product continues to gain market acceptance, the Company expects sales in 2012 and beyond to continually increase.

 

There can be no assurances that the Company will be able to achieve its projected level of revenues in 2012 and beyond.  If the Company is unable to achieve its projected revenues and is not able to obtain alternate additional financing of equity or debt, the Company would need to significantly curtail or reorient its operations during 2012, which could have a material adverse effect on the Company’s ability to achieve its business objectives and as a result may require the Company to file for bankruptcy or cease operations.  The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts classified as liabilities that might be necessary should the Company be forced to take any such actions.

 

Sources and Uses of Cash

 

For the six months ended June 30, 2012 and 2011, net cash used by operations was $845,100 and $810,462, respectively.  The negative cash flow for the six months ended June 30, 2012 was primarily the result of the $1,269,517 net loss.  This was reduced by several non-cash charges, primarily the share-based compensation charges of $289,160 and $252,950 for amortization. The negative cash flow for the six months ended June 30, 2011 was primarily the result of the $2,320,641 net loss.  This was reduced by several non-cash charges, primarily the share-based compensation charges of $735,682 and $755,581 for amortization.

 

Net cash used by investing activities for the six months ended June 30, 2012 was $24,819 compared to net cash provided by investing activities for the same period of 2011 of $35,549.   The cash used in 2012 was due to legal and other costs associated with our patents and trademarks.    

 

Net cash provided by financing activities for the six months ended June 30, 2012 and 2011, was $1,240,174 and $810,711, respectively. The cash provided in 2012 was primarily from the issuance of common stock, $1,189,049, as well as proceeds of $61,125 from the related party line of credit. This was offset by a $10,000 payment for deferred financing costs. In 2011, the cash provided was from the issuance of notes payable of $525,000, proceeds from the related party line of credit of $633,750, and issuance of common stock from the exercise of warrants of $41,250 offset by financing costs incurred of $389,289.

 

Our future expenditures and capital requirements will depend on numerous factors, including: the rate at which we can introduce and sell NRL to manufacturers; the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; and market acceptance of our products and competing technological developments. We expect that we will incur approximately $1.2 million for operating expenses over the next 12 months.  As we expand our activities and operations, our cash requirements are expected to increase at a rate consistent with revenue growth after we have achieved sustained revenue generation.

 

We expect that our cash used in operations will continue to increase as a result of the following planned activities:

 

· The addition of staff to our workforce as needs arise;
· Increased spending for the expansion of our research and development efforts, including clinical trials, regulatory submissions, assistance with manufacturing trials and product enhancements;
· Increased spending in marketing as our products are introduced into the marketplace;
· Increases in our general and administrative activities related to our operations as a reporting public company and related corporate compliance requirements.

 

Off-Balance Sheet Arrangements

 

 We do not have any off-balance sheet arrangements that may be reasonably likely to have a current or future material effect on our financial condition, liquidity, or results of operations.

 

17
 

 

DISCLOSURE REGARDING FORWARD-LOOKING STATEMENTS

 

Our Management’s Discussion and Analysis contains not only statements that are historical facts, but also statements that are forward-looking (within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934). Forward-looking statements are, by their very nature, uncertain and risky. These risks and uncertainties include international, national and local general economic and market conditions; demographic changes; our ability to sustain, manage, or forecast growth;  product development, introduction and acceptance; existing government regulations and changes in, or the failure to comply with, government regulations; adverse publicity; competition; fluctuations and difficulty in forecasting operating results; changes in business strategy or development plans; business disruptions; the ability to attract and retain qualified personnel; the ability to protect technology; and other risks that might be detailed from time to time in our filings with the Securities and Exchange Commission.

 

Although the forward-looking statements in this Quarterly Report reflect the good faith judgment of our management, such statements can only be based on facts and factors currently known by them. Consequently, and because forward-looking statements are inherently subject to risks and uncertainties, the actual results and outcomes may differ materially from the results and outcomes discussed in the forward-looking statements. You are urged to carefully review and consider the various disclosures made by us in this report and in our other reports as we attempt to advise interested parties of the risks and factors that may affect our business, financial condition, and results of operations and prospects.

 

18
 

 

ITEM 3.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not required.

 

ITEM  4.  CONTROLS AND PROCEDURES

 

  (A) Evaluation of disclosure controls and procedures

 

Our management, including our principal executive and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures as of June 30, 2012.  Our disclosure controls and procedures are designed to provide reasonable assurance that the information required to be disclosed in this quarterly report on Form 10-Q has been appropriately recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive and principal financial officer, to allow timely decisions regarding required disclosure.  Based on that evaluation, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures are effective to the reasonable assurance level.

 

  (B) Changes in internal control over financial reporting

 

We regularly review our system of internal control over financial reporting and make changes to our processes and systems to improve controls and increase efficiency, while ensuring that we maintain an effective internal control environment.  Changes may include such activities as implementing new, more efficient systems, consolidating activities, and migrating processes.

 

There were no changes in our internal control over financial reporting that occurred during the second quarter of 2012 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

  (C) Limitations on the Effectiveness of Controls

 

We have confidence in our internal controls and procedures. Nevertheless, our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure procedures and controls or our internal controls will prevent all errors or intentional fraud. An internal control system, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of such internal controls are met. Further, the design of an internal control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all internal control systems, no evaluation of controls can provide absolute assurance that all our control issues and instances of fraud, if any, have been detected.

 

19
 

 

PART II.  OTHER INFORMATION

 

ITEM 1.    LEGAL PROCEEDINGS

 

None.

 

ITEM 2.    UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

Set forth below is information regarding shares of common stock, warrants and options to purchase common stock issued by the Company in the quarter ended June 30, 2012, that were not registered under the Securities Act of 1933, as amended (the “Securities Act”). Also included is the consideration, if any, received by the Company for such shares, warrants and options and information relating to the section of the Securities Act, or rule of the Securities and Exchange Commission, under which exemption from registration was claimed.

 

(a)   Common Stock and Warrant Financings  

 

From April 1, 2012 through June 30, 2012, the Company issued 2,340,000 shares of its common stock at $0.25 per share and 2,300,000 warrants to purchase one share of common stock at an exercise price of $0.35 per share.

 

From April 1, 2012 through June 30, 2012, the Company issued 148,000 shares of its common stock valued at $48,390 for services rendered to the Company.

 

From April 1, 2012 through June 30, 2012, the Company issued warrants to purchase 318,053 shares of common stock for services rendered to the Company per the following:

 

Warrants   Exercise Price Per Share  
171,285   $ 0.35  
2,500   $ 0.30  
144,268   $ 0.28  

 

(b)   Stock Option Grants

 

None.

 

(c)   Application of Securities Laws and Other Matters

 

No underwriters were involved in the foregoing sales of securities. The securities described in section (a) of this Item 2 were issued to investors in reliance upon the exemption from the registration requirements of the Securities Act, as set forth in Section 4(2) under the Securities Act and Regulation D promulgated thereunder, as applicable, relative to sales by an issuer not involving any public offering, to the extent an exemption from such registration was required.

 

All of the foregoing securities are deemed restricted securities for purposes of the Securities Act. All certificates representing the issued shares of common stock, warrants and options described in this Item 2 included appropriate legends setting forth that the securities had not been registered and the applicable restrictions on transfer.

 

20
 

 

ITEM 3.  DEFAULTS UPON SENIOR SECURITIES

 

None

 

ITEM 4.         MINE SAFETY DISCLOSURES

 

 Not applicable

 

 

ITEM 5.  OTHER INFORMATION

 

None

 

ITEM 6.         EXHIBITS

 

Exhibit Index *

* Some Exhibits have certain confidential information redacted pursuant to a request for confidential treatment

Number   Description
3.1   Articles of Incorporation of Vystar Acquisition Corporation (now named Vystar Corporation) dated December 17, 2003 (as amended) (incorporated by reference to Vystar’s Registration Statement on Form S-1 originally filed on November 13, 2008, Registration Statement No. 333-155344)
     
3.2   Bylaws of Vystar Corporation (incorporated by reference to Vystar’s Registration Statement on Form S-1 originally filed on November 13, 2008, Registration Statement No. 333-155344)
     
4.1   Specimen Certificate evidencing shares of Vystar common stock (incorporated by reference to Vystar’s Registration Statement on Form S-1 originally filed on November 13, 2008, Registration Statement No. 333-155344)

 

4.2   Form of Share Subscription Agreements and Investment Letter (First Private Placement) (incorporated by reference to Vystar’s Registration Statement on Form S-1 originally filed on November 13, 2008, Registration Statement No. 333-155344)
     
4.3   Form of Share Subscription Agreement and Investment Letter (Second Private Placement) (incorporated by reference to Vystar’s Registration Statement on Form S-1 originally filed on November 13, 2008, Registration Statement No. 333-155344)
     
4.4   Form of Vystar Corporation Investor Questionnaire and Subscription Agreement (Third Private Placement) (incorporated by reference to Vystar’s Registration Statement on Form S-1 originally filed on November 13, 2008, Registration Statement No. 333-155344)
     
4.5   Warrant to Purchase Shares of Common Stock of Vystar Corporation dated March 11, 2011 issued to Topping Lift Capital LLC (incorporated by reference to Vystar’s Current Report on Form 8-K dated March 11, 2011 and filed on March 15, 2011)
     
4.6   Form of Warrant issued to Investor note holders (incorporated by reference to Vystar’s Current Report on Form 8-K dated March 11, 2011 and filed on March 15, 2011)
     
4.7   Form of Series A Warrant (incorporated by reference to Vystar’s Current Report on Form 8-K filed on June 11, 2012)

 

10.1*   Manufacturing Agreement between Vystar Corporation and Revertex (Malaysia) Sdn. Bhd. effective April 1, 2008 (incorporated by reference to Vystar’s Registration Statement on Form S-1 originally filed on November 13, 2008, Registration Statement No. 333-155344)
     
10.2   Executive Employment Agreement between Vystar Corporation and William R. Doyle, dated November 11, 2008 (incorporated by reference to Vystar’s Registration Statement on Form S-1 originally filed on November 13, 2008, Registration Statement No. 333-155344)

 

21
 

 

10.3   Management Agreement dated January 31, 2008 between Universal Capital Management, Inc. and Vystar Corporation (incorporated by reference to Vystar’s Registration Statement on Form S-1 originally filed on November 13, 2008, Registration Statement No. 333-155344)
     
10.4   Letter Agreement dated August 15, 2008 between Universal Capital Management, Inc. and Vystar Corporation  (incorporated by reference to Vystar’s Registration Statement on Form S-1 originally filed on November 13, 2008, Registration Statement No. 333-155344)
     
10.5   Addendum to Management Agreement dated February 29, 2008 between Universal Capital Management, Inc. and Vystar Corporation (incorporated by reference to Vystar’s Registration Statement on Form S-1 originally filed on November 13, 2008, Registration Statement No. 333-155344)
     
10.6   Warrant Purchase Agreement dated January 31, 2008 between Universal Capital Management, Inc. and Vystar Corporation (incorporated by reference to Vystar’s Registration Statement on Form S-1 originally filed on November 13, 2008, Registration Statement No. 333-155344)
     
10.7   Management Agreement dated April 30, 2008 between Universal Capital Management, Inc. and Vystar Corporation (incorporated by reference to Vystar’s Registration Statement on Form S-1 originally filed on November 13, 2008, Registration Statement No. 333-155344)
     
10.8   Warrant Purchase Agreement dated April 30, 2008 between Universal Capital Management, Inc. and Vystar Corporation (incorporated by reference to Vystar’s Registration Statement on Form S-1 originally filed on November 13, 2008, Registration Statement No. 333-155344)
     
10.9   Vystar Corporation 2004 Long-Term Compensation Plan, as amended (incorporated by reference to Vystar’s Registration Statement on Form S-1 originally filed on November 13, 2008, Registration Statement No. 333-155344)
     
10.10   First Amendment to Employment Agreement dated July 1, 2009, between Vystar Corporation and Sandra Parker (incorporated by reference to Vystar’s Registration Statement on Form S-1 originally filed on November 13, 2008, Registration Statement No. 333-155344)
     
10.10*   Distributor Agreement among Vystar Corporation, Centrotrade Minerals & Metals, Inc. and Centrotrade Deutschland, GmbH dated January 6, 2009 (incorporated by reference to Vystar’s Registration Statement on Form S-1 originally filed on November 13, 2008, Registration Statement No. 333-155344)
     
10.11   Note agreement between Vystar Corporation and Climax Global Energy, Inc. dated August 15, 2008 (incorporated by reference to Vystar’s Registration Statement on Form S-1 originally filed on November 13, 2008, Registration Statement No. 333-155344)
     
10.12   Form of Investor Note (incorporated by reference to Vystar’s Current Report on Form 8-K dated March 11, 2011 and filed on March 15, 2011)
     
10.13   Promissory Grid Note dated April 29, 2011, in a principal amount of $800,000 from Vystar Corporation to CMA Investments, LLC (incorporated by reference to Vystar’s Current Report on Form 8-K dated April 29, 2011 and filed on May 2, 2011)
     
10.14   First Amendment to Agreement dated September 9, 2011, between Vystar Corporation, CMA Investments, LLC and Italia-Eire, LP, a Georgia limited partnership (incorporated by reference to Vystar’s Annual Report on Form 10-K dated March 30, 2012, and filed on March 30, 2012) 
     
10.15   Form of Securities Purchase Agreement dated May 4, 2012

 

31.1   Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
31.2   Certification of Chief Financial Officer pursuant Section 302 of the Sarbanes-Oxley Act of 2002
     
32.1   Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as  adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
     
101   The following financial information from the Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2012, formatted in XBRL (Extensible Business Reporting Language) and furnished electronically herewith: (i) Balance Sheets; (ii) Statements of Income; (iii) Statements of Cash Flows; and (iv) Notes to Financial Statements.

 

22
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  VYSTAR CORPORATION
     
Date:  August 10, 2012 By:   /s/ William R. Doyle
  William R. Doyle
 

Chairman, President, Chief Executive Officer and

Director (Principal Executive Officer)

     
Date: August 10, 2012 By: /s/ Linda S. Hammock
  Linda S. Hammock
 

Acting Chief Financial Officer

(Principal Financial and Accounting Officer)

 

23
 

 

VYSTAR CORPORATION

 

SECURITIES PURCHASE AGREEMENT

 

This Securities Purchase Agreement (“ Agreement ”) is made as of May __, 2012, by and between Vystar Corporation, a Georgia corporation (the “ Company ”), and each of the purchasers who execute the Purchaser Signature Page hereto (the “ Purchaser ”).

 

RECITALS

 

A.            The Company desires to obtain funds from each Purchaser in order to provide working capital for marketing, acquisitions, expansion and to further the operations of the Company.

 

B.            The Company is offering Units (the “ Units ”), each Unit comprised of (i) 100,000 shares of its common stock, $0.001 par value per share (the “ Common Stock ” and, the shares of Common Stock offered herein, being sometimes referred to herein as the “ Shares ”), and (ii) 100,000 warrants in the form as annexed hereto as Exhibit A (the “ Warrants ”), to purchase an equal number of shares of Common Stock at an exercise price of $0.35 per share (the “ Warrant Shares ”), at a purchase price of $25,000 per Unit (i.e. $0.25 per Share and Warrant). The Shares, Warrants and Warrant Shares are sometimes collectively referred to herein as the “ Securities .”

 

C.            Purchasers understand that there is a great deal of risk, illiquidity and uncertainty in the purchase of the Units herein, and that no assurance can be made that the Company will complete its business plan or, if completed, that it will be successful in doing so. Purchasers have received and examined all of the Company’s SEC Reports (as defined in Section 3.7.1), including, without limitation, any risk factors therein, and a Offering Summary Memorandum dated as of May 4, 2012 (the “ PPM ”) containing such information as, among other things, a description of this offering and understand that an investment herein entails a high degree of risk and illiquidity, including loss of Purchaser’s entire investment.

 

D.            The offering of Units is being made directly by the Company through the Placement Agent (as hereinafter defined), to accredited investors only, under Regulation S and/or Rule 506 of Regulation D of the Securities Act, as amended, on a “best efforts $750,000 maximum” basis, wherein up to a maximum of 30 Units, or 3,000,000 Shares and3,000,000 Warrants may be sold.

 

E.            There is no escrow agent in this offering and moneys will not be held in any segregated or secured account pending acceptance or rejection. Accordingly, there is also no minimum offering amount and your funds reflecting the Purchase Price will become immediately available for use by the Company and susceptible to rights of third party creditors without protection. Purchasers and third party agents will not have an opportunity to approve of a Closing / subscription acceptance, or to request refund of any moneys submitted to the Company until such time as subscriptions are accepted or rejected or a Termination Date occurs. Purchasers acknowledge and agree that their subscriptions are irrevocable and binding commitments on the part of the Purchaser and that once their funds have been tendered with the appropriate subscription documents the Company may utilize and disburse funds and conduct a Closing and issue to Purchasers their respective Shares and Warrants without any advanced consent or notice to Purchasers or the Placement Agent. The Company may reject any subscriptions in whole or in part for any reason or for no reason to return funds to the Purchaser to the extent of such non accepted funds, or, retains the right to hold the same for acceptance or rejection at a future closing, until termination of the offering, at which time, any unused subscription funds shall be returned to Purchaser.

 

 
 

 

AGREEMENT

 

It is agreed as follows:

 

1.           PURCHASE AND SALE OF UNITS.

 

1.1            Purchase and Sale . In reliance upon the representations and warranties of the Company and each Purchaser contained herein and subject to the terms and conditions set forth herein, at Closing, each Purchaser shall purchase, and the Company shall sell and issue to each Purchaser, Units comprised of the number of Shares and Warrants set forth on the signature page annexed to the end of this Agreement as executed by such Purchaser (the “ Purchaser Signature Page ”), issued in such Purchaser’s name, at a purchase price of $25,000 per Unit (the “ Purchase Price ”).

 

2.           CLOSING.

 

2.1            Date and Time . The sale of Units will take place in one or more closings (“ Closing ”), subject to the satisfaction of all the parties hereto of their obligations herein. The Purchasers shall submit an executed copy of this Agreement to the Company and Placement Agent along with the Purchase Price by bank wire (or, with the consent of Placement Agent, by check) directly to the Company. The Closing of the sale of Units contemplated by this Agreement shall take place from time to time as subscriptions are received, without any consent of, or notice to, Purchasers. Subscriptions that are not accepted will be returned with any funds (less wire fees). The Closing shall take place at the offices of the Company or at such other place as the Company and the Placement Agent shall agree in writing (each, a “ Closing Date ”) on or before May 15, 2012, unless otherwise extended by the Company and Placement Agent up to a maximum of 30 days (the “ Termination Date ”).

 

2.2            No Escrow Agent . There is no escrow agent and no minimum offering amount. Purchasers understand and acknowledge that the Company may or may not raise capital other than their own subscription and, that the Company may accept subscriptions from Purchasers at any time. Purchasers acknowledge and agree that their subscriptions are irrevocable and binding commitments on the part of the Purchaser and that once their funds have been tendered to the Company with the appropriate subscription documents and their subscription received. The Company may reject any subscriptions in whole or in part for any reason or for no reason and shall return funds to the Purchaser to the extent of such non accepted funds, or, retains the right to hold the same for acceptance or rejection at a future closing, until the Termination Date of the offering, at which time, any unused subscription funds shall be returned to Purchaser.

 

3.           REPRESENTATIONS AND WARRANTIES OF THE COMPANY.

 

As a material inducement to each Purchaser to enter into this Agreement and to purchase the Units and for Placement Agent to assist in placing the offering, the Company represents and warrants that the following statements are true and correct in all material respects as of the date hereof and will be true and correct in all material respects at Closing, except as expressly qualified or modified herein. All references in this Section 3 to the Shares, Warrants or Warrant Shares or Securities shall be deemed to include the Placement Agent Shares, Placement Agent Warrants (each as defined in Section 8 below) and shares issuable upon exercise of the Placement Agent Warrants, unless the context requires otherwise.

 

3.1            Organization and Good Standing . The Company is a corporation duly organized, validly existing, and in good standing under the laws of the State of Georgia and has full corporate power and authority to enter into and perform its obligations under this Agreement, and to own its properties and to carry on its business in all jurisdictions as presently conducted and as proposed to be conducted. The Company and its subsidiaries have all government and other licenses and permits and authorizations to do business in all jurisdictions where their activities require such license, permits and authorizations, except where failure to obtain any such license, permit or authorization will not have a Material Adverse Effect, as defined herein.

 

2
 

 

3.2            Capitalization . As of March 31, 2012, the Company is authorized to issue 50,000,000 shares of Common Stock, of which, 19,032,248 shares were issued and outstanding, and 15,000,000 shares of “blank check” preferred stock authorized, none of which is or has been issued or outstanding or designated or otherwise agreed to be issued or outstanding and none of which has been or is designated as a series or class with any specific rights or privileges. All outstanding shares of the Company’s capital stock have been duly authorized and validly issued, and are fully paid, nonassessable, and free of any preemptive rights. There is only one class and series of common stock of the Company, without any special series, rights, preferences or designations assigned to any particular shares of Common Stock. The Company does not have any outstanding notes, convertible debt, derivative securities or notes other than as specifically set forth on Schedule 3.2 hereto which are convertible into or exercisable for Common Stock, and which do not have anti dilution rights or protections.

 

3.3            Authorization . The Company has full power and authority and has taken all requisite action on the part of the Company, its officers, directors and stockholders necessary for (i) the authorization, execution and delivery of this Agreement, the Warrants and any other transaction documents relating to this Agreement (collectively the “ Transaction Documents ”), (ii) the authorization of the performance of all obligations of the Company hereunder or thereunder, and (iii) the authorization, issuance (or reservation for issuance) and delivery of the Shares hereby or the Warrant Shares upon exercise of the Warrants . The Transaction Documents constitute the legal, valid and binding obligations of the Company, enforceable against the Company in accordance with their terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability, relating to or affecting creditors’ rights generally.

 

3.4            Valid Issuance of Securities . The Shares have been duly and validly authorized and, upon issuance, will be validly issued, fully paid and non-assessable. The Warrants have been duly and validly authorized, and, the Warrant Shares, when and if issued in accordance with the terms of the Warrants, shall be validly issued, fully paid and non-assessable. The Shares, upon issuance are, and the Warrant Shares, upon issuance in accordance with the Warrants will be, free and clear of any security interests, liens, claims or other encumbrances, other than restrictions upon transfer under federal and state securities laws. The shares of each Subsidiary are duly authorized, validly issued, fully paid and non assessable and held by the Company which has sole, and unencumbered marketable title and is the sole owner.

 

3.5            No Conflict, Breach, Violation or Default; Third Party Consents . Th e execution, delivery and performance of the Transaction Documents by the Company and the issuance and sale of the Securities will not conflict with or result in a breach or violation of any of the terms and provisions of, or constitute a default under (i) the Company’s Articles of Incorporation or the Company’s Bylaws, both as in effect on the date hereof (collectively, the “ Company Documents ”), or (ii) any statute, rule, regulation or order of any governmental agency, self regulatory agency, securities regulatory or insurance regulatory agency or body or any court, domestic or foreign, having jurisdiction over the Company or any of its assets or properties, or (iii) any material agreement or instrument to which the Company is a party or by which the Company is bound or to which any of its assets or properties is subject; except in the case of each of clauses (ii) and (iii), such as could not, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect. No approval of or filing with any governmental authority is required for the Company to enter into, execute or perform this Agreement or any Transaction Document.

 

3
 

 

3.6            No Material Adverse Change . Since December 31, 2011, except as identified and described in the SEC Reports (as defined below) or as described on Schedule 3.6 , there has not been:

 

(i)          any change in the assets, liabilities, financial condition or operating results of the Company from that reflected in the financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2011 except for changes in the ordinary course of business which have not had and could not reasonably be expected to have a material adverse effect on the Company’s assets, properties, financial condition, operating results or business of the Company taken as a whole other than an effect primarily or proximately resulting from (A) changes in general economic or market conditions affecting the industry generally in which the Company operates, which changes do not disproportionately affect the Company as compared to other similarly situated participants in the industry in which the Company operates; (B) changes in applicable law or GAAP; and (C) acts of terrorism, war or natural disasters which do not disproportionately affect the Company (as such business is presently conducted) (a “ Material Adverse Effect ”), individually or in the aggregate;

 

(ii)         any declaration or payment of any dividend, or any authorization or payment of any distribution, on any of the capital stock of the Company, or any redemption or repurchase of any securities of the Company;

 

(iii)        any material damage, destruction or loss, whether or not covered by insurance, to any assets, licenses, government permits, self regulatory agency permit or license, or properties of the Company;

 

(iv)        any waiver, not in the ordinary course of business, by the Company of a material right or of a material debt owed to it;

 

(v)         any satisfaction or discharge of any lien, claim or encumbrance or payment of any obligation by the Company, except in the ordinary course of business and which has not had a Material Adverse Effect;

 

(vi)        any change or amendment to the Company Documents, or material change to any material contract or arrangement by which the Company is bound or to which any of its assets or properties is subject;

 

(vii)       any material labor difficulties, labor disputes, non-compete or similar disputes, or labor union organizing activities with respect to employees of the Company;

 

(viii)      any material transaction entered into by the Company other than in the ordinary course of business;

 

(ix)         the loss of the services of any key employee, salesperson, or material change in the composition or duties of the senior management of the Company;

 

(x)          the loss or threatened loss of any customer which has had or could reasonably be expected to have a Material Adverse Effect;

 

(xi)         any default of any indebtedness or, to the knowledge of the Company, breach of contract agreement, in each case with aggregate liabilities of greater than $50,000.

 

4
 

 

(xi)         any other event or condition of any character that has had or could reasonably be expected to have a Material Adverse Effect.

 

3.7            SEC Reports and Financial Statements .

 

3.7.1           The Company has made available to each Purchaser through the SEC’s EDGAR system accurate and complete copies (excluding copies of exhibits) of each report, registration statement, and definitive proxy statement filed by the Company with the United States Securities and Exchange Commission (“ SEC ”) since December 31, 2010 (collectively, the “ SEC Reports ”). All statements, reports, schedules, forms and other documents required to have been filed by the Company with the SEC have been so filed. As of the time it was filed with the SEC (or, if amended or superseded by a filing prior to the date of this Agreement, then on the date of such filing): (i) each of the SEC Reports complied in all material respects with the applicable requirements of the Securities Act of 1933, as amended (the “ Securities Act ”), or the Securities Exchange Act of 1934 (the “ 1934 Act ”), as amended; and (ii) none of the SEC Reports contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.

 

3.7.2           Except for the pro forma financial statements, if any, the financial statements contained in the SEC Reports: (i) complied as to form in all material respects with the published rules and regulations of the SEC applicable thereto at the time of filing and as of the date of each Closing; (ii) were prepared in accordance with GAAP applied on a consistent basis throughout the periods covered (except as may be indicated in the notes to such financial statements and, in the case of unaudited statements, as permitted by Form 10-Q of the SEC, and except that unaudited financial statements may not contain footnotes and are subject to normal and recurring year-end audit adjustments which will not, individually or in the aggregate, be material in amount); and (iii) fairly present, in all material respects, the financial position of the Company as of the respective dates thereof and the results of operations of the Company for the periods covered thereby, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments. All adjustments considered necessary for a fair presentation of the financial statements have been included.

 

3.8            Securities Law Compliance . Without consideration of the actions of the Placement Agent (as defined in Section 8 herein), and assuming the accuracy of the representations and warranties of each Purchaser set forth in Section 4 of this Agreement, the offer and sale of the Securities comprising the Units will constitute an exempted transaction under the Securities Act, and registration of the Shares, Warrants or Warrant Shares under the Securities Act for issuance herein is not required. The Company shall make such filings as may be necessary to comply with the Federal securities laws and the “blue sky” laws of any state in connection with the offer and sale of the Securities, which filings will be made in a timely manner.

 

3.9            Tax Matters . The Company has timely prepared and filed all tax returns required to have been filed by the Company with all appropriate governmental agencies and timely paid all taxes shown thereon or otherwise owed by it. The charges, accruals and reserves on the books of the Company in respect of taxes for all fiscal periods are adequate in all material respects, and there are no material unpaid assessments against the Company nor, to the Company’s Knowledge, any basis for the assessment of any additional taxes, penalties or interest for any fiscal period or audits by any federal, state or local taxing authority except for any assessment which is not material to the Company, taken as a whole. All taxes and other assessments and levies that the Company is required to withhold or to collect for payment have been duly withheld and collected and paid to the proper governmental entity or third party when due. There are no tax liens or claims pending or, to the Company’s Knowledge, threatened against the Company or any of its assets or property. There are no outstanding tax sharing agreements or other such arrangements between the Company or other corporation or entity. For the purposes of this agreement, “ Company’s Knowledge ” means the actual knowledge of the executive officers (as defined in Rule 405 under the Securities Act) of the Company.

 

5
 

 

3.10          Title to Properties . Except as disclosed in the SEC Reports, the Company has good and marketable title to all real properties and all other properties and assets owned by it, in each case free from liens, encumbrances and defects that would materially affect the value thereof or materially interfere with the use made or currently planned to be made thereof by them; and except as disclosed in the SEC Reports, the Company holds any leased real or personal property under valid and enforceable leases with no exceptions that would materially interfere with the use made or currently planned to be made thereof by them.

 

3.11          Intellectual Property .

 

Except as set forth in Schedule 3.11 :

 

(i)          All Intellectual Property of the Company or its Subsidiaries is currently in compliance with all legal requirements (including timely filings, proofs and payments of fees) and is valid and enforceable. No Intellectual Property of the Company which is necessary for the conduct of Company’s businesses as currently conducted has been or is now involved in any cancellation, dispute or litigation, and, to the Company’s Knowledge, no such action is threatened.

 

(ii)         All of the licenses and sublicenses and consent, royalty or other agreements concerning Intellectual Property which are necessary for the conduct of the Company’s business as currently conducted to which the Company is a party or by which any of its assets are bound (other than generally commercially available, non-custom, off-the-shelf software application programs having a retail acquisition price of less than $10,000 per license) (collectively, “ License Agreements ”) are valid and binding obligations of the Company and, to the Company’s Knowledge, the other parties thereto, enforceable in accordance with their terms, except to the extent that enforcement thereof may be limited by bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance or other similar laws affecting the enforcement of creditors’ rights generally, and there exists no event or condition which will result in a material violation or breach of or constitute (with or without due notice or lapse of time or both) a default by the Company under any such License Agreement.

 

(iii)        The Company owns or has the valid right to use all of the Intellectual Property that is necessary for the conduct of the Company’s business as currently conducted and for the ownership, maintenance and operation of the Company’s properties and assets, free and clear of all liens, encumbrances, adverse claims or obligations to license all such owned Intellectual Property and Confidential Information, other than licenses entered into in the ordinary course of the Company’s business. The Company has a valid and enforceable right to use all third party Intellectual Property and Confidential Information used or held for use in the business of the Company.

 

(iv)        To the Company’s Knowledge, the conduct of the Company’s business as currently conducted does not infringe or otherwise impair or conflict with (collectively, “ Infringe ”) any Intellectual Property rights of any third party or any confidentiality obligation owed to a third party, and, to the Company’s Knowledge, the Intellectual Property and Confidential Information of the Company which are necessary for the conduct of the Company’s business as currently conducted are not being Infringed by any third party. There is no litigation or order pending or outstanding or, to the Company’s Knowledge, threatened or imminent, that seeks to limit or challenge or that concerns the ownership, use, validity or enforceability of any Intellectual Property or Confidential Information of the Company and the Company’s use of any Intellectual Property or Confidential Information owned by a third party, and, to the Company’s Knowledge, there is no valid basis for the same.

 

6
 

 

(v)         The consummation of the transactions contemplated hereby and by the other Transaction Documents will not result in the alteration, loss, impairment of or restriction on the Company’s ownership or right to use any of the Intellectual Property or Confidential Information which is necessary for the conduct of the Company’s business as currently conducted.

 

(vi)        The Company has taken reasonable steps to protect the Company’s rights in its Intellectual Property and Confidential Information. Each employee, consultant and contractor who has had access to Confidential Information which is necessary for the conduct of Company’s business as currently conducted has executed an agreement to maintain the confidentiality of such Confidential Information and has executed appropriate agreements that are substantially consistent with the Company’s standard forms thereof, except where the failure to do so has not had and could not reasonably be expected to have a Material Adverse Effect, individually or in the aggregate. Except under confidentiality obligations, there has been no material disclosure of any Confidential Information to any third party.

 

3.12          Environmental Matters . To the Company’s Knowledge, the Company (i) is not in violation of any statute, rule, regulation, decision or order of any governmental agency or body or any court, domestic or foreign, relating to the use, disposal or release of hazardous or toxic substances or relating to the protection or restoration of the environment or human exposure to hazardous or toxic substances (collectively, “ Environmental Laws ”), (ii) does not own or operate any real property contaminated with any substance that is subject to any Environmental Laws, (iii) is not liable for any off-site disposal or contamination pursuant to any Environmental Laws, or (iv) is not subject to any claim relating to any Environmental Laws, which violation, contamination, liability or claim has had or could reasonably be expected to have a Material Adverse Effect, individually or in the aggregate; and there is no pending or, to the Company’s Knowledge, threatened investigation that might lead to such a claim.

 

3.13          Litigation . There are no pending material actions, suits or proceedings against or affecting the Company, or any of its properties; and to the Company’s Knowledge, no such actions, suits or proceedings are threatened or contemplated against the Company.

 

3.14          No Directed Selling Efforts or General Solicitation . Neither the Company nor any Person, as defined below, acting on its behalf has conducted any general solicitation or general advertising (as those terms are used in Regulation D) in connection with the offer or sale of any of the Securities. “ Person ” means any individual, corporation, company, limited liability company, partnership, limited liability partnership, trust, estate, proprietorship, joint venture, association, organization or entity.

 

3.15          No Integrated Offering . Neither the Company nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers or sales of any Company security or solicited any offers to buy any security, under circumstances that would adversely affect reliance by the Company on Section 4(2) for the exemption from registration for the transactions contemplated hereby or would require registration of the Securities under the Securities Act. For purposes of this Agreement, “ Affiliate ” means, with respect to any Person, any other Person which directly or indirectly through one or more intermediaries Controls, is controlled by, or is under common control with, such Person.

 

7
 

 

3.16          Questionable Payments . To the Company’s Knowledge, none of its current or former stockholders, directors, officers, employees, agents or other Persons acting on behalf of the Company, has on behalf of the Company or in connection with its business: (i) used any corporate funds for unlawful contributions, gifts, entertainment or other unlawful expenses relating to political activity; (ii) made any direct or indirect unlawful payments to any governmental officials or employees from corporate funds; (iii) established or maintained any unlawful or unrecorded fund of corporate monies or other assets; (iv) made any false or fictitious entries on the books and records of the Company; or (v) made any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment of any nature.

 

3.17          Transactions with Affiliates . Except as disclosed in the SEC Reports, none of the officers or directors of the Company and, to the Company’s Knowledge, none of the employees of the Company is presently a party to any transaction with the Company (other than as holders of stock options and/or warrants, and for services as employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise requiring payments to or from any officer, director or such employee or, to the Company’s Knowledge, any entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee or partner.

 

3.18          Internal Controls . Except as set forth in the SEC Reports, the Company is in material compliance with the provisions of the Sarbanes-Oxley Act of 2002 currently applicable to the Company except where such noncompliance could not have or reasonably be expected to result in a Material Adverse Effect. Except as set forth in the SEC Reports, the Company maintains, and will use commercially reasonable best efforts to maintain, a system of internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial statements and to maintain asset accountability both in conformity with GAAP and the applicable provisions of the 1934 Act, (iii) access to assets is permitted only in accordance with management’s general or specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. Except as set forth in the SEC Reports, the Company has established disclosure controls and procedures (as defined in the 1934 Act Rules 13a-14 and 15d-14) and designed such disclosure controls and procedures to ensure that material information relating to the Company, including the subsidiaries, is made known to the certifying officers by others within those entities, particularly during the period in which the Company’s most recently filed period report under the 1934 Act, as the case may be, is being prepared. The Company’s certifying officers have evaluated the effectiveness of the Company’s controls and procedures as of the end of the period covered by the most recently filed periodic report under the 1934 Act (such date, the “ Evaluation Date ”). The Company presented in its most recently filed periodic report under the 1934 Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no significant changes in the Company’s internal controls (as such term is defined in Item 308 of Regulation S-K for smaller reporting companies) or, to the Company’s Knowledge, in other factors that could significantly affect the Company’s internal controls.

 

3.19          Disclosures . Neither the Company, the Placement Agent, nor any Person acting on any of their behalf has provided the Purchasers or their agents or counsel with any information that constitutes or might constitute material, non-public information. The written materials delivered to the Purchasers in connection with the transactions contemplated by the Transaction Documents do not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements contained therein, in light of the circumstances under which they were made, not misleading.

 

8
 

 

3.20          Third Party Beneficiaries . The Company acknowledges that Placement Agent, its representatives, and other selling agents (if any), are direct intended beneficiaries of the representations and warranties made hereby in respect of all of the Placement Agent Shares or Warrants issued to them or their affiliates, and, are also deemed third party beneficiaries to the representations and warranties made hereby to the Purchasers.

 

4.          REPRESENTATIONS AND WARRANTIES OF EACH PURCHASER.

 

Each Purchaser individually and not jointly hereby represents warrants and covenants with the Company as follows. For avoidance of doubt, these warranties and representations are made to the Company as well as to the Placement Agent and their agents and representatives and affiliates and other members of the selling group (if any) and their representatives and affiliates, as third party beneficiaries hereto:

 

4.1            Legal Power . Each Purchaser has the requisite individual, corporate, partnership, limited liability company, trust, or fiduciary power, as appropriate, and is authorized, if such Purchaser is a corporation, partnership, limited liability company, or trust, to enter into this Agreement, to purchase the Shares hereunder, and to carry out and perform its obligations under the terms of this Agreement or any other Transaction Documents to which it is a party.

 

4.2            Due Execution . The execution and performance of the terms under this Agreement and the Accredited Investor Questionnaire commencing Page SP-2 appended at the end of this Agreement (the “ Questionnaire ”) and Purchaser Signature Page hereto, have been duly authorized, if such Purchaser is a corporation, partnership, limited liability company, trust or fiduciary, executed and delivered by such Purchaser, and, upon due execution and delivery by the Company, this Agreement will be a valid and binding agreement of such Purchaser.

 

4.3            Access to Information . Each Purchaser understands that an investment in the Securities involves a high degree of risk and illiquidity, including, risk of loss of their entire investment. Each Purchaser also understands that the Company has limited capital and is not profitable. Each Purchaser represents that such Purchaser has been given full and complete access to the Company for the purpose of obtaining such information as such Purchaser or its qualified representative has reasonably requested in connection with the decision to purchase the Shares. Each Purchaser represents that such Purchaser has received and reviewed copies of the SEC Reports and PPM. Each Purchaser represents that such Purchaser has been afforded the opportunity to ask questions of the officers of the Company regarding its business prospects and the Shares, all as such Purchaser or such Purchaser’s qualified representative have found necessary to make an informed investment decision to purchase the Shares.

 

4.4            Restricted Securities .

 

4.4.1           Each Purchaser has been advised that none of the Securities have been registered under the Securities Act or any other applicable securities laws and that Shares are being offered and sold pursuant to Section 4(2) of the Securities Act and/or Rule 506 of Regulation D and/or Regulation S thereunder, and that the Company’s reliance upon Section 4(2) and/or Rule 506 of Regulation D and/or Regulation S is predicated in part on such Purchaser representations as contained herein (including, for avoidance of doubt, the Questionnaire). Each Purchaser acknowledges that the Securities will be issued as “restricted securities” as defined by Rule 144 promulgated pursuant to the Securities Act. None of the Securities may be resold in the absence of an effective registration thereof under the Securities Act and applicable state securities laws unless, in the opinion of counsel reasonably satisfactory to the Company, an applicable exemption from registration is available.

 

9
 

 

4.4.2           Each Purchaser represents that such Purchaser is acquiring the Shares for such Purchaser’s own account, and not as nominee or agent, for investment purposes only and not with a view to, or for sale in connection with, a distribution, as that term is used in Section 2(11) of the Securities Act, in a manner which would require registration under the Securities Act or any state securities laws.

 

4.4.3           Each Purchaser understands and acknowledges that the certificates representing the Shares, Warrants and, if issued, the Warrant Shares, will bear substantially the following legend:

 

“THE SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR APPLICABLE STATE LAW, AND NO INTEREST THEREIN MAY BE SOLD, DISTRIBUTED, ASSIGNED, OFFERED, PLEDGED OR OTHERWISE TRANSFERRED UNLESS (i) THERE IS AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS COVERING ANY SUCH TRANSACTION INVOLVING SAID SECURITIES, (ii) THE COMPANY RECEIVES AN OPINION OF LEGAL COUNSEL REASONABLY SATISFACTORY TO THE COMPANY STATING THAT SUCH TRANSACTION IS EXEMPT FROM REGISTRATION, OR (iii) THE COMPANY OTHERWISE SATISFIES ITSELF THAT SUCH TRANSACTION IS EXEMPT FROM REGISTRATION.”

 

4.4.4           Each Purchaser acknowledges that an investment in the Shares is not liquid and is transferable only under limited conditions. Each Purchaser acknowledges that such securities must be held indefinitely unless they are subsequently registered under the Securities Act or an exemption from such registration is available. Each Purchaser is aware of the provisions of Rule 144 promulgated under the Securities Act, which permits limited resale of restricted securities subject to the satisfaction of certain conditions and that such Rule is not now available and, in the future, may not become available for resale of any of the Securities. Each Purchaser is an “accredited investor” as defined under Rule 501 under the Securities Act.

 

4.4.5           The representations made by each Purchaser on the Questionnaire (commencing page SP-2 appended at the end hereof) and Purchaser Signature Page are true and correct.

 

4.5            Purchaser Sophistication and Ability to Bear Risk of Loss . Each Purchaser acknowledges that it is able to protect its interests in connection with the acquisition of the Shares and can bear the economic risk of investment in such securities without producing a material adverse change in such Purchaser’s financial condition. Each Purchaser, either alone or with such Purchaser’s representative(s), otherwise has such knowledge and experience in financial or business matters that such Purchaser is capable of evaluating the merits and risks of the investment in the Securities.

 

4.6            Purchases by Groups . Each Purchaser represents, warrants and covenants that it is not acquiring the Shares as part of a group within the meaning of Section 13(d)(3) of the 1934 Act or otherwise purchasing with intent to control voting over the Company.

 

4.7            Independent Investigation . Each Purchaser in making his decision to purchase the Units herein, has relied solely upon an independent investigation made by him and his legal, tax and/or financial advisors and, is not relying upon any oral representations of the Company or the Placement Agent.

 

4.8            No Advertising . Each Purchaser has not received any general solicitation or advertising regarding the offer of the Units.

 

10
 

 

4.9            Certain Trading Activities . Each Purchaser has not directly or indirectly, nor has any person acting on behalf of or pursuant to any understanding with such Purchaser, engaged in any transactions in the securities of the Company (including, without limitation, any short sales involving the Company’s securities) since the time that such Purchaser was first contacted by the Company or the Placement Agent regarding the investment in the Company contemplated by this Agreement. Each Purchaser covenants that neither it nor any person acting on its behalf or pursuant to any understanding with it will engage in any transactions in the securities of the Company (including short sales) prior to the time that the transactions contemplated by this Agreement are publicly disclosed.

 

4.10          Placement Agent Review . Each Purchaser acknowledges that neither Bradley Woods & Co. Ltd., as “Placement Agent,” nor any of Placement Agent’s representatives, sub-agents, or affiliates, has made a purchase recommendation, research report or provided a rating, opinion, buy or sell recommendation, or, independently verified the accuracy, completeness, materiality or otherwise, of any information, representation or warranty contained in this Purchase Agreement, the SEC Reports, or any offering materials provided, that such placement agent related entities and their principals shall have no liability for any representation (express or implied) contained in, or for any omissions from, the Purchase Agreement or any offering documents provided or any other written or oral communications transmitted to the recipient in the course of his or her evaluation of the investment, and that it is understood that each prospective investor will make an independent investigation and analysis of a potential investment in the Company with its legal, tax or financial advisors, and will be relying upon same in making any such investment.

 

4.11          Regulation S; Non-U.S. Person Status . For purposes of compliance with the Regulation S exemption for the offer and sale of the Securities to non-U.S. Persons, if the Purchaser is not a “U.S. Person,” as such term is defined in Rule 902(k) of Regulation S, 1 the Purchaser represents and warrants they are a person or entity that is outside the United Sates, and further represents and warrants as follows:

 

 

  1 Regulation S provides in part as follows:

 

1. “U.S. person” means: (i) any natural person resident in the United States; (ii) any partnership or corporation organized or incorporated under the laws of the United States; (iii) any estate of which any executor or administrator is a U.S. person; (iv) any trust of which any trustee is a U.S. person; (v) any agency or branch of a foreign entity located in the United States; (vi) any non-discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary for the benefit or account of a U.S. person; (vii) any discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary organized, incorporated, or (if an individual) resident in the United States; and (viii) any partnership or corporation if: (A) organized or incorporated under the laws of any foreign jurisdiction; and (B) formed by a U.S. person principally for the purpose of investing in securities not registered under the Securities Act of 1933, as amended, unless it is organized or incorporated, and owned, by accredited investors (as defined in Rule 501(a)) who are not natural persons, estates or trusts.

 

2. The following are not “U.S. persons”: (i) any discretionary account or similar account (other than an estate or trust) held for the benefit or account of a non-U.S. person by a dealer or other professional fiduciary organized, incorporated, or (if an individual) resident in the United States; (ii) any estate of which any professional fiduciary acting as executor or administrator is a U.S. person if: (A) an executor or administrator of the estate who is not a U.S. person has sole or shared investment discretion with respect to the assets of the estate; and (B) the estate is governed by foreign law; (iii) any trust of which any professional fiduciary acting as trustee is a U.S. person, if a trustee who is not a U.S. person has sole or shared investment discretion with respect to the trust assets, and no beneficiary of the trust (and no settler if the trust is revocable) is a U.S. person; (iv) an employee benefit plan established and administered in accordance with the law of a country other than the United States and customary practices and documentation of such country; (v) any agency or branch of a U.S. person located outside the United States if: (A) the agency or branch operates for valid business reasons; and (B) the agency or branch is engaged in the business of insurance or banking and is subject to substantive insurance or banking regulation, respectively, in the jurisdiction where located; and (vi) the International Monetary Fund, the International Bank for Reconstruction and Development, the Inter-American Development Bank, the Asian Development Bank, the African Development Bank, the United Nations, and their agencies, affiliates and pension plans, and any other similar international organizations, their agencies, affiliates and pension plans.

 

11
 

 

4.11.1 The Purchaser is not acquiring the Securities for the account or benefit of a U.S. Person.

 

4.11.2 If the Purchaser is a legal entity, it has not been formed specifically for the purpose of investing in the Company.

 

4.11.3 The Purchaser hereby represents that he, she or it has satisfied and fully observed the laws of the jurisdiction in which he, she or it is located or domiciled, in connection with the acquisition of the Securities, including (i) the legal requirements of the Purchaser’s jurisdiction for the acquisition of the Securities, (ii) any foreign exchange restrictions applicable to such acquisition, (iii) any governmental or other consents that may need to be obtained, and (iv) the income tax and other tax consequences, if any, which may be relevant to the holding, redemption, sale, or transfer of the Securities; and further, the Purchaser agrees to continue to comply with such laws as long as he, she or it shall hold the Investment Securities.

 

4.11.4 To the knowledge of the Purchaser, without having made any independent investigation, neither the Company nor any person acting for the Company, has conducted any “directed selling efforts” in the United States as the term “directed selling efforts” is defined in Rule 902 of Regulation S, which, in general, means any activity undertaken for the purpose of, or that could reasonably be expected to have the effect of, conditioning the marketing in the United States for any of the Securities being offered. Such activity includes, without limitation, the mailing of printed material to investors residing in the United States, the holding of promotional seminars in the United States, and the placement of advertisements with radio or television stations broadcasting in the United States or in publications with a general circulation in the United States, which discuss the offering of the Investment Securities. To the knowledge of the Purchaser, the Securities were not offered to the undersigned through, and the undersigned is not aware of, any form of general solicitation or general advertising, including without limitation, (i) any advertisement, article, notice or other communication published in any newspaper, magazine or similar media or broadcast over television or radio, and (ii) any seminar or meeting whose attendees have been invited by any general solicitation or general advertising.

 

4.11.5 The Purchaser will offer, sell or otherwise transfer the Securities, only (A) pursuant to a registration statement that has been declared effective under the Securities Act, (B) pursuant to offers and sales that occur outside the United States within the meaning of Regulation S in a transaction meeting the requirements of Rule 904 (or other applicable Rule) under the Securities Act, or (C) pursuant to another available exemption from the registration requirements of the Securities Act, subject to the Company’s right prior to any offer, sale or transfer pursuant to clauses (B) or (C) to require the delivery of an opinion of counsel, certificates or other information reasonably satisfactory to the Company for the purpose of determining the availability of an exemption.

 

12
 

 

4.11.6 The Purchaser will not engage in hedging transactions involving the Securities unless such transactions are in compliance with the Securities Act.

 

4.11.7 The Purchaser represents and warrants that the undersigned is not a citizen of the United States and is not, and has no present intention of becoming, a resident of the United States (defined as being any natural person physically present within the United States for at least 183 days in a 12-month consecutive period or any entity who maintained an office in the United States at any time during a 12-month consecutive period). The Purchaser understands that the Company may rely upon the representations and warranty of this paragraph as a basis for an exemption from registration of the Securities under the Securities Act of 1933, as amended, and the provisions of relevant state securities laws.

 

5.          [Omitted].

 

6.          COVENANTS OF THE COMPANY AND PURCHASER

 

6.1            Use of Proceeds . The Company intends to employ the net proceeds from the purchase and sale of the Shares for purposes of working capital, marketing, acquisitions, expansion and to further the operations of the Company only and not for the repayment of any single existing debt in excess of $100,000.

 

6.2            Registration Rights . For purposes of this Section 6.2, all references to the Purchaser shall be deemed to mean and include, the Purchaser, Placement Agent and their respective assigns as holders of Registrable Securities (as defined in Section 6.2.1(b) below).

 

6.2.1          Notice of Registration . If the Company shall determine to register any of its securities under the Securities Act in connection with the public offering of such securities, either for its own account or the account of a security holder, other than (A) a registration relating to employee benefit plans, (B) a registration relating to Rule 145 or similar transaction, and (C) a registration on any form that does not include substantially the same information as could be required to be included in a registration statement covering the sale of Registrable Securities, the Company will:

 

(a)          promptly give to each Purchaser written notice thereof; and

 

(b)          use commercially reasonable efforts to include in such registration (and any related qualification under blue sky laws or other compliance), and in any underwriting involved therein, all the Registrable Securities specified in a written request or requests, made within twenty (20) days after receipt of such written notice from the Company, by any such Purchaser, except as set forth in Section 6.2.2 below. In the event that the Company decides for any reason not to complete the registration of securities other than Registrable Securities as part of an underwritten public offering it shall specify that such Registrable Securities are to be included in the underwriting on the same terms and conditions as the securities otherwise being sold through underwriters under such registration.

 

Registrable Securities ” means the following, unless the Company’s underwriters deem that registration of such shares might materially injure an offering by the Company, (i) the Shares, (ii) the Warrant Shares and, (ii) any Placement Agent or Sub-Agent Shares and Warrants issued to the Placement Agent, Sub-Agents or their/its assigns pursuant to the terms of this Agreement or any agreement with the Placement Agent calling for compensation relating hereto, which have not been registered under the Securities Act pursuant to an effective registration statement filed thereunder; provided, however, that the Purchasers shall not be required to exercise the Warrants in order to have the Warrant Shares included in any registration statement filed on the appropriate form with, and declared effective by, the SEC under the Securities Act and covering the resale by the Purchasers of the Registrable Securities (a “ Registration Statement ”).

 

13
 

 

6.2.2         Registration Process . In connection with the registration of the Registrable Securities pursuant to Section 6.2.1, the Company shall:

 

(a)          Prepare and file with the SEC the Registration Statement and such amendments (including post effective amendments) to the Registration Statement and supplements to the prospectus included therein (a “ Prospectus ”) as the Company may deem necessary or appropriate and take all lawful action such that the Registration Statement and any amendment thereto does not, when it becomes effective, contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, not misleading and that the Prospectus forming part of the Registration Statement, and any amendment or supplement thereto, does not at any time during the period commencing on the effective date of the Registration Statement and ending on the date on which all of the Registrable Securities may be sold to the public without registration under the Securities Act in reliance on Rule 144 (the “ Registration Period ”) include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading;

 

(b)          Comply with the provisions of the Securities Act with respect to the Registrable Securities covered by the Registration Statement until the earlier of (i) such time as all of such Registrable Securities have been disposed of in accordance with the intended methods of disposition by each Purchaser as set forth in the Prospectus forming part of the Registration Statement or (ii) the date on which the Registration Statement is withdrawn;

 

(c)          Furnish to each Purchaser and its legal counsel identified to the Company (i) promptly after the same is prepared and publicly distributed, filed with the SEC, or received by the Company, one copy of the Registration Statement, each Prospectus, and each amendment or supplement thereto, and (ii) such number of copies of the Prospectus and all amendments and supplements thereto and such other documents, as the Purchaser may reasonably request in order to facilitate the disposition of the Registrable Securities;

 

(d)          Register or qualify the Registrable Securities covered by the Registration Statement under such securities or “blue sky” laws of such jurisdictions as the Purchasers reasonably request, (ii) prepare and file in such jurisdictions such amendments (including post effective amendments) and supplements to such registrations and qualifications as may be necessary to maintain the effectiveness thereof at all times during the Registration Period, (iii) take all such other lawful actions as may be necessary to maintain such registrations and qualifications in effect at all times during the Registration Period, and (iv) take all such other lawful actions reasonably necessary or advisable to qualify the Registrable Securities for sale in such jurisdictions; provided, however , that the Company shall not be required in connection therewith or as a condition thereto to (A) qualify to do business in any jurisdiction where it would not otherwise be required to qualify, (B) subject itself to general taxation in any such jurisdiction or (C) file a general consent to service of process in any such jurisdiction;

 

(e)          As promptly as practicable after becoming aware of such event, notify each Purchaser of the occurrence of any event, as a result of which the Prospectus included in the Registration Statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading, and promptly prepare an amendment to the Registration Statement and supplement to the Prospectus to correct such untrue statement or omission, and deliver a number of copies of such supplement and amendment to each Purchaser as such Purchaser may reasonably request;

 

14
 

 

(f)          As promptly as practicable after becoming aware of such event, notify each Purchaser (or, in the event of an underwritten offering, the managing underwriters) of the issuance by the SEC of any stop order or other suspension of the effectiveness of the Registration Statement and take all lawful action to effect the withdrawal, rescission or removal of such stop order or other suspension;

 

(g)          Take all such other lawful actions reasonably necessary to expedite and facilitate the disposition by the Purchaser of its Registrable Securities in accordance with the intended methods therefor provided in the Prospectus which are customary under the circumstances;

 

(h)          In the event of an underwritten offering, promptly include or incorporate in a Prospectus supplement or post effective amendment to the Registration Statement such information as the underwriters reasonably agree should be included therein and to which the Company does not reasonably object and make all required filings of such Prospectus supplement or post effective amendment as soon as practicable after it is notified of the matters to be included or incorporated in such Prospectus supplement or post effective amendment;

 

(i)          In connection with any underwritten offering, deliver such documents and certificates as may be reasonably required by the underwriters; and

 

(j)          Cooperate with the Purchasers to facilitate the timely preparation and delivery of certificates representing Registrable Securities to be sold pursuant to the Registration Statement, which certificates shall, if required under the terms of this Agreement, be free of all restrictive legends, and to enable such Registrable Securities to be in such denominations and registered in such names as any Purchaser may request and maintain a transfer agent for the Common Stock.

 

6.2.3          Obligations and Acknowledgements of the Purchasers . In connection with the registration of the Registrable Securities, each Purchaser shall have the following obligations and hereby make the following acknowledgements:

 

(a)          It shall be a condition precedent to the obligations of the Company to include the Registrable Securities in the Registration Statement that each Purchaser wishing to participate in the Registration Statement (i) shall furnish to the Company such information regarding itself, the Registrable Securities held by it and the intended method of disposition of the Registrable Securities held by it as shall be reasonably required to effect the registration of such Registrable Securities and (ii) shall execute such documents in connection with such registration as the Company may reasonably request. Prior to the first anticipated filing date of a Registration Statement, the Company shall notify each Purchaser of the information the Company requires from such Purchaser (the “ Requested Information ”) if such Purchaser elects to have any of its Registrable Securities included in the Registration Statement. If a Purchaser notifies the Company and provides the Company the information required hereby prior to the time the Registration Statement is declared effective, the Company will file an amendment to the Registration Statement that includes the Registrable Securities of such Purchaser provided, however , that the Company shall not be required to file such amendment to the Registration Statement at any time less than five (5) business days prior to the effective date.

 

(b)          Each Purchaser agrees to cooperate with the Company in connection with the preparation and filing of a Registration Statement hereunder, unless such Purchaser has notified the Company in writing of its election to exclude all of its Registrable Securities from such Registration Statement;

 

15
 

 

(c)          Each Purchaser agrees that, upon receipt of any notice from the Company of the occurrence of any event of the kind described in Section 6.2.2(e) or 6.2.2(f), such Purchaser shall immediately discontinue its disposition of Registrable Securities pursuant to the Registration Statement covering such Registrable Securities until the Purchaser’s receipt of the copies of the supplemented or amended Prospectus contemplated by Section 6.2.2(e) and, if so directed by the Company, the Purchaser shall deliver to the Company (at the expense of the Company) or destroy (and deliver to the Company a certificate of destruction) all copies in the Purchaser’s possession, of the Prospectus covering such Registrable Securities current at the time of receipt of such notice; and

 

(d)          Each Purchaser acknowledges that it may be deemed to be a statutory underwriter within the meaning of the Securities Act with respect to the Registrable Securities being registered for resale by it, and if a Purchaser includes Registrable Securities for offer and sale within a Registration Statement such Purchaser hereby consents to the inclusion in such Registration Statement of a disclosure to such effect.

 

6.2.4          Expenses of Registration . All expenses (other than underwriting discounts and commissions and the fees and expenses of a Purchaser’s counsel) incurred in connection with registrations, filings or qualifications pursuant to this Section 6.2, including, without limitation, all registration, listing, and qualifications fees, printing and engraving fees, accounting fees, and the fees and disbursements of counsel for the Company, shall be borne by the Company.

 

6.2.5          Indemnification and Contribution .

 

(a)           Indemnification by the Company . The Company shall indemnify and hold harmless each Purchaser and each underwriter, if any, which facilitates the disposition of Registrable Securities, and each of their respective officers and directors and each Person who controls such underwriter within the meaning of Section 15 of the Securities Act or Section 20 of the 1934 Act (each such Person being sometimes hereinafter referred to as an “ Indemnified Person ”) from and against any losses, claims, damages or liabilities, joint or several, to which such Indemnified Person may become subject under the Securities Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon an untrue statement or alleged untrue statement of a material fact contained in any Registration Statement or an omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein, not misleading, or arise out of or are based upon an untrue statement or alleged untrue statement of a material fact contained in any Prospectus or an omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading; and the Company hereby agrees to reimburse such Indemnified Person for all reasonable legal and other expenses incurred by them in connection with investigating or defending any such action or claim as and when such expenses are incurred; provided, however, that the Company shall not be liable to any such Indemnified Person in any such case to the extent that any such loss, claim, damage or liability arises out of or is based upon (i) an untrue statement or alleged untrue statement made in, or an omission or alleged omission from, such Registration Statement or Prospectus in reliance upon and in conformity with written information furnished to the Company by such Indemnified Person expressly for use therein or (ii) in the case of the occurrence of an event of the type specified in Section 6.2.2(e), the use by the Indemnified Person of an outdated or defective Prospectus after the Company has provided to such Indemnified Person an updated Prospectus correcting the untrue statement or alleged untrue statement or omission or alleged omission giving rise to such loss, claim, damage or liability.

 

16
 

 

(b)           Indemnification by the Purchasers and Underwriters . Each Purchaser agrees, as a consequence of the inclusion of any of its Registrable Securities in a Registration Statement, and each underwriter, if any, which facilitates the disposition of Registrable Securities shall agree, severally and not jointly, as a consequence of facilitating such disposition of Registrable Securities to (i) indemnify and hold harmless the Company, its directors (including any person who, with his or her consent, is named in the Registration Statement as a director nominee of the Company), its officers who sign any Registration Statement and each Person, if any, who controls the Company within the meaning of either Section 15 of the Securities Act or Section 20 of the 1934 Act, against any losses, claims, damages or liabilities to which the Company or such other persons may become subject, under the Securities Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon an untrue statement or alleged untrue statement of a material fact contained in such Registration Statement or Prospectus or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein (in light of the circumstances under which they were made, in the case of the Prospectus), not misleading, in each case to the extent, but only to the extent, that such untrue statement or alleged untrue statement or omission or alleged omission was made in reliance upon and in conformity with written information furnished to the Company by the Purchaser or underwriter expressly for use therein, and (ii) reimburse the Company for any legal or other expenses incurred by the Company in connection with investigating or defending any such action or claim as such expenses are incurred; provided, however, that such Purchaser shall not be liable under this Section 6.2.5(b) for any amount in excess of the net proceeds paid to such Purchaser in respect of Registrable Securities sold by it.

 

(c)           Notice of Claims, etc . Promptly after receipt by a Person seeking indemnification pursuant to this Section 6.2.5 (an “ Indemnified Party ”) of written notice of any investigation, claim, proceeding or other action in respect of which indemnification is being sought (each, a “ Claim ”), the Indemnified Party promptly shall notify the Person against whom indemnification pursuant to this Section 6.2.5 is being sought (the “ Indemnifying Party ”) of the commencement thereof; but the omission to so notify the Indemnifying Party shall not relieve it from any liability that it otherwise may have to the Indemnified Party, except to the extent that the Indemnifying Party is materially prejudiced and forfeits substantive rights and defenses by reason of such failure. In connection with any Claim as to which both the Indemnifying Party and the Indemnified Party are parties, the Indemnifying Party shall be entitled to assume the defense thereof. Notwithstanding the assumption of the defense of any Claim by the Indemnifying Party, the Indemnified Party shall have the right to employ separate legal counsel and to participate in the defense of such Claim, and the Indemnifying Party shall bear the reasonable fees, out of pocket costs and expenses of such separate legal counsel to the Indemnified Party if (and only if): (i) the Indemnifying Party shall have agreed to pay such fees, costs and expenses, (ii) the Indemnified Party shall reasonably have concluded that representation of the Indemnified Party by the Indemnifying Party by the same legal counsel would not be appropriate due to actual or, as reasonably determined by legal counsel to the Indemnified Party, potentially differing interests between such parties in the conduct of the defense of such Claim, or if there may be legal defenses available to the Indemnified Party that are in addition to or disparate from those available to the Indemnifying Party, or (iii) the Indemnifying Party shall have failed to employ legal counsel reasonably satisfactory to the Indemnified Party within a reasonable period of time after notice of the commencement of such Claim. If the Indemnified Party employs separate legal counsel in circumstances other than as described in the preceding sentence, the fees, costs and expenses of such legal counsel shall be borne exclusively by the Indemnified Party. Except as provided above, the Indemnifying Party shall not, in connection with any Claim in the same jurisdiction, be liable for the fees and expenses of more than one firm of counsel for the Indemnified Party (together with appropriate local counsel). The Indemnified Party shall not, without the prior written consent of the Indemnifying Party (which consent shall not unreasonably be withheld), settle or compromise any Claim or consent to the entry of any judgment that does not include an unconditional release of the Indemnifying Party from all liabilities with respect to such Claim or judgment or contain any admission of wrongdoing.

 

17
 

 

(d)           Contribution . If the indemnification provided for in this Section 6.2.5 is unavailable to or insufficient to hold harmless an Indemnified Party in respect of any losses, claims, damages or liabilities (or actions in respect thereof) referred to therein, then each Indemnifying Party shall contribute to the amount paid or payable by such Indemnified Party as a result of such losses, claims, damages or liabilities (or actions in respect thereof) in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party and the Indemnified Party in connection with the statements or omissions or alleged statements or omissions which resulted in such losses, claims, damages or liabilities (or actions in respect thereof), as well as any other relevant equitable considerations. The relative fault of such Indemnifying Party and Indemnified Party shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied by such Indemnifying Party or by such Indemnified Party, and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. The parties hereto agree that it would not be just and equitable if contribution pursuant to this Section 6.2.5(d) were determined by pro rata allocation (even if the Purchasers or any underwriters were treated as one entity for such purpose) or by any other method of allocation which does not take account of the equitable considerations referred to in this Section 6.2.5(d). The amount paid or payable by an Indemnified Party as a result of the losses, claims, damages or liabilities (or actions in respect thereof) referred to above shall be deemed to include any legal or other fees or expenses reasonably incurred by such Indemnified Party in connection with investigating or defending any such action or claim. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.

 

(e)           Limitation on Purchasers’ and Underwriters’ Obligations . Notwithstanding any other provision of this Section 6.2.5, in no event shall (i) any Purchaser have any liability under this Section 6.2.5 for any amounts in excess of the dollar amount of the proceeds actually received by such Purchaser from the sale of Registrable Securities (after deducting any fees, discounts and commissions applicable thereto) pursuant to any Registration Statement under which such Registrable Securities are registered under the Securities Act and (ii) any underwriter be required to undertake liability to any Person hereunder for any amounts in excess of the aggregate discount, commission or other compensation payable to such underwriter with respect to the Registrable Securities underwritten by it and distributed pursuant to the Registration Statement.

 

(f)           Other Liabilities . The obligations of the Company under this Section 6.2.5 shall be in addition to any liability which the Company may otherwise have to any Indemnified Person and the obligations of any Indemnified Person under this Section 6.2.5 shall be in addition to any liability which such Indemnified Person may otherwise have to the Company. The remedies provided in this Section 6.2.5 are not exclusive and shall not limit any rights or remedies which may otherwise be available to an indemnified party at law or in equity.

 

6.2.6         Rule 144 . With a view to making available to the Purchasers the benefits of Rule 144, the Company agrees to use its best efforts to:

 

(a)          comply with the provisions of paragraph (c)(1) of Rule 144; and

 

(b)          file with the SEC in a timely manner all reports and other documents required to be filed by the Company pursuant to Section 13 or 15(d) under the 1934 Act; and, if at any time it is not required to file such reports but in the past had been required to or did file such reports, it will, upon the request of any Purchasers, make available other information as required by, and so long as necessary to permit sales of, its Registrable Securities pursuant to Rule 144.

 

18
 

 

6.2.7         Common Stock Issued Upon Stock Split, etc. The provisions of this Section 6.2 shall apply to any shares of Common Stock or any other securities issued as a dividend or distribution in respect of the Shares or the Warrant Shares.

 

6.2.8         Termination of Registration Rights . The registration rights granted in this Section 6.2 shall terminate with respect to a Security upon the date such Security is first eligible to be resold pursuant to Rule 144 of the Securities Act.

 

6.3           [Omitted.]

 

6.4.          [Omitted.]

 

6.5.           Additional Share Issuances; Full Ratchet Share Adjustment .

 

6.5.1         Full Ratchet Adjustment . In the event that at any time commencing the first Closing and continuing for a period of twelve (12) months following the final Closing or termination of the offering of Units offered in this entire offering, except for Excepted Issuances (as defined in Section 6.5.3), the Company shall agree to issue or actually issue or grant the right to receive any Common Stock, preferred securities, or securities convertible, exercisable or exchangeable for shares of Common Stock (or modify any of the foregoing which may be outstanding) (“ Common Stock Equivalent ”) to any person or entity at a price per share or conversion price or exercise price per share (the “ Lower Per Share Price ”) which shall be less than the per share purchase price of initially $0.25 insert per share purchase price in this offering, as adjusted for stock splits, dividends and reclassifications, (the “ Per Share Price ”) then in effect (“ Lower Price Issuance ”), then, automatically and without any obligation of or notice to Purchaser or Finders, the Per Share Price paid herein shall be amended, reduced, restated and deemed to be equal to such number of additional shares of Common Stock (the “ Additional Shares ”) as equals the sum of the Purchase Price paid hereby as set forth on the signature page hereto, divided by the Lower Per Share Price, less the number Shares previously issued to the Purchaser. Thereafter, and for purposes of calculating future adjustments or issuances of Additional Shares, the Per Share Price shall be amended and revised to be the Lower Per Share Price. Certificates for Additional Shares shall be unconditionally delivered by Federal Express to the Placement Agent on behalf of both itself and the Purchasers within 7 business days of the date of the Lower Price Issuance of Common Stock or Common Stock Equivalents (or, if earlier, date of commitment to make the Lower Price Issuance of Common Stock or Common Stock Equivalents). The Company acknowledges and agrees that the Purchasers and the Placement Agent and their assigns may be irreparably harmed and injured (including loss of profits) if certificates of Additional Shares are not issued promptly in accordance with the provisions hereof and shall compensate, in addition to enforcement costs, any lost profits or expenses of Purchaser, the Placement Agent, or their rightful assigns in the event that a court finds in favor of such any of such persons in any action by such persons to enforce their rights. Notwithstanding the foregoing, and for avoidance of doubt, adjustments and issuance of Additional Shares shall only be issued and granted if and to the extent that Share holders hold Shares at the time of issuance or commitment for such Common Stock Equivalent transaction.

 

6.5.2         Effective Price . For purposes of Section 6.5 , in connection with any issuance of any Common Stock Equivalents, (i) the maximum number of Common Stock potentially issuable at any time upon conversion, exercise or exchange of such Common Stock Equivalents (the “ Deemed Number ”) shall be deemed to be outstanding or subscribed for and required to be issued upon issuance of such Common Stock Equivalents, (ii) the deemed issue price (“ Effective Price ”) applicable to such Common Stock Equivalents shall equal the minimum dollar value of consideration payable to the Company to purchase such Common Stock Equivalents and to convert, exercise or exchange them into Common Stock, divided by the Deemed Number, and (iii) no further adjustment shall be made to the Per Share Price upon the actual issuance of Common Stock upon conversion exercise or exchange of such Common Stock Equivalents if issued at or higher than the Effective Price. Common Stock issued or issuable by the Company for no consideration will be deemed to have been issued or to be issuable for $0.001 per share of Common Stock. 

 

19
 

 

 

6.5.3          Excepted Issuances . For purposes of Section 6.5, “ Excepted Issuance ” shall mean in respect to: (i) Common Stock or Common Stock Equivalents issued in connection with this Agreement or otherwise related to this Agreement for other or subsequent investors in said offering, (ii) the Company’s issuance of Common Stock or Common Stock Equivalents upon the exercise or conversion of options, warrants or convertible notes or other securities, outstanding on the date hereof as specifically described in Reports (but not if the amounts and exercise prices of the same are not both already described in the Reports) or specifically disclosed herein, (iii) grants or issuances to officers, directors or employees or other service providers in connection with Board approved (including majority of disinterested and independent board members) stock option, stock, incentive or similar plan granted to officers, directors or employees and other service providers, (iv) up to 1,000,000 shares issued to unaffiliated service providers for bona-fide services not pursuant to any plan, provided that such issuances are approved by the Board, (v) the issuance of securities as full or partial consideration in connection with a bona fide merger, asset acquisition, joint venture or reorganization (other than a mere reincorporation transaction) approved by the Board of Directors of the Company and the majority of disinterested members of the Board, and (vi) issuances of up to 1,000,000 warrants to purchase Common Stock to executive officers of the Company pursuant to its existing plan to allow such executive officers to receive warrants to purchase Common Stock in lieu of regularly scheduled cash compensation. For avoidance of doubt, the foregoing Excepted Issuance exceptions shall only apply during the period in which anti dilution adjustments are made for Lower Price Issuances in accordance with Section 6.5. Common Stock issued or issuable by the Company for services will be deemed to have been issued or to be issued for the value booked in the Company’s public financial statements, or as booked on the recipients 1099 or other tax reporting by the Company in connection with such issuance, whichever is higher.

 

6.6            Filing of Reports . The Company will use best efforts to file on a timely basis, any and all reports or amendments thereto, as it is required to file in order to remain fully current with all of its reporting obligations under the Exchange Act so as to enable sales without resale limitations 6 months from the date of first Closing, pursuant to Rule 144, as amended (“ Rule 144 Sales ”). It is expressly agreed and acknowledged that the Company’s obligation pursuant to this Section 6.4 shall extend only until the period ending 12 months from the date of final Closing, after which time such obligation shall terminate automatically. The Company acknowledges and understands that its failure to make such filings on a timely basis could cause irreparable injury to Purchasers and Placement Agent, both with respect to the Shares and Warrant Shares owned by them and that the Company may be subject to liability therefore, including, without limitation, actual lost profits as the result of any failure to file the required reports on a timely basis. Accordingly, if during the period commencing 6 months from the date of the first Closing and ending 12 months from the date of final Closing, the Company fails to maintain a current filing status with the SEC to allow Rule 144 Sales, a holder of a Unit shall be entitled to liquidated damages of 1% per calendar month capped at the dollar amount such holder invested; provided, however, that an affiliate of the Company shall not be entitled to such liquidated damages. For avoidance of doubt, all references herein to filings to be made on a “timely basis” shall include and mean, any extension periods permissible under Rule 12b-25 of the Exchange Act, provided that the Company has complied with such rule, but not beyond said extension date. 

 

20
 

 

7.           CONDITIONS

 

7.1           Conditions Precedent to the Obligation of the Company to Close and to Sell the Shares . The obligation hereunder of the Company to close and issue and sell the Shares to the Purchasers at a Closing is subject to the satisfaction or waiver, at or before such Closing of the conditions set forth below. These conditions are for the Company’s and Placement Agent’s sole benefit and may be waived by the Company and Placement Agent at any time in their sole discretion.

 

7.1.1          Accuracy of the Purchasers’ Representations and Warranties . The representations and warranties of each Purchaser (including, for avoidance of doubt, those relating to the Questionnaire) shall be true and correct in all material respects as of the date when made and as of such Closing as though made at that time, except for representations and warranties that are expressly made as of a particular date, which shall be true and correct in all material respects as of such date.

 

7.1.2          Performance by the Purchasers . Each Purchaser shall have performed, satisfied, and complied in all material respects with all covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Purchasers at or prior to such Closing.

 

7.1.3          No Injunction . No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by any court or governmental authority of competent jurisdiction which prohibits the consummation of any of the transactions contemplated by this Agreement.

 

7.1.4          Delivery of Purchase Price . The Purchase Price for the Shares shall be available in cleared funds and authorized by the Company and Placement Agent, in their sole and absolute discretion, for distribution on such Closing in accordance with the terms hereof.

 

7.1.5          Delivery of Transaction Documents . The Transaction Documents shall have been duly executed and delivered by the Purchasers to the Company.

 

7.2            Conditions Precedent to the Obligation of the Purchasers to Close and to Purchase the Shares . The obligation hereunder of the Purchasers to purchase the Shares and consummate the transactions contemplated by this Agreement is subject to the satisfaction or waiver, at or before such Closing, of each of the conditions set forth below. These conditions are for the Purchasers’ sole benefit and may be waived by the Purchasers and Placement Agent at any time in their sole discretion.

 

7.2.1          Accuracy of the Company’s Representations and Warranties . Each of the representations and warranties of the Company in this Agreement and the other Transaction Documents shall be true and correct in all material respects as of such Closing, except for representations and warranties that speak as of a particular date, which shall be true and correct in all material respects as of such date.

 

7.2.2          Performance by the Company . The Company shall have performed, satisfied and complied in all material respects with all covenants, agreements and conditions required by this Agreement to be performed, satisfied or complied with by the Company at or prior to such Closing.

 

7.2.3          No Suspension, Etc . Trading in the Common Stock of the Company shall not have been suspended by the SEC or the OTC Bulletin Board (except for any suspension of trading of limited duration agreed to by the Company, which suspension shall be terminated prior to the Closing)..

 

21
 

 

7.2.4          No Injunction . No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by any court or governmental authority of competent jurisdiction which prohibits the consummation of any of the transactions contemplated by this Agreement.

 

7.2.5          No Proceedings or Litigation . No action, suit or proceeding before any arbitrator or any governmental authority shall have been commenced, and no investigation by any governmental authority shall have been initiated, against the Company, or any of the officers, directors or affiliates of the Company seeking to restrain, prevent or change the transactions contemplated by this Agreement, or seeking damages in connection with such transactions.

 

7.2.6          Shares and Warrants . At the Closing, the Company shall have delivered to the Purchasers the Warrants and the Shares and shall have delivered to the Placement Agent the Placement Agent’s Warrants and Placement Agent’s Shares along with all appropriate board resolutions or other necessary documentation in order to issue the Shares in such denominations as each Purchaser may request. The Company shall also deliver this Agreement, duly executed by the Company.

 

7.2.7          Secretary’s Certificate . The Company shall deliver to the Placement Agent, a secretary’s certificate, dated as of the each Closing Date, as to (i) the resolutions adopted by the Board of Directors approving the transactions contemplated hereby, (ii) the Company’s Articles of Incorporation, (iii) the Bylaws, each as in effect at such Closing, and (iv) the authority and incumbency of the officers of the Company executing the Transaction Documents and any other documents required to be executed or delivered in connection therewith.

 

7.2.8          Officer’s Certificate . On the first Closing Date, the Company shall have delivered to the Placement Agent a certificate signed by an executive officer on behalf of the Company, dated as of such first Closing Date, confirming the accuracy of the Company’s representations, warranties, and covenants as of such first Closing Date and confirming the compliance by the Company with the conditions precedent set forth in paragraph 7.2.9 as of such Closing.

 

7.2.9            Material Adverse Effect . No Material Adverse Effect shall have occurred at or before such Closing Date.

 

7.2.10          Opinion of Counsel . Counsel for the Company shall have delivered to the Placement Agent, an opinion, in reasonably satisfactory form, to the effect of the due/valid issuance of all Securities, due authority, validity, binding effect of all related agreements and the Warrants and, no defaults or conflicts caused by this Agreement and related transactions. Notwithstanding that New York law governs this Agreement, such opinion may be given under Georgia law on the assumption that the laws of the states of New York and Georgia are identical.

 

7.2.11          Lock Up Agreement . All executive officers and directors of the Company inclusive of their affiliated entities that may beneficially own shares of the Company, shall execute a lock up agreement and agree to notify and file such agreement with the Company’s transfer agent to effectively impose a stop sale notice with respect to their shares of the Company, to the effect that such persons may not sell, assign, transfer, pledge or hypothecate any shares held or acquired by them, from commencement of the offering and continuing for a period of 365 days following the final closing of the offering and, thereafter, sales may only be made by such persons in accordance with the resale limitations set forth for them, as applicable, under Rule 144 of the Securities Act.

 

22
 

 

8.           PLACEMENT AGENT/LEGAL FEES.

 

8.1            Placement Agent’s Commissions; Sub-Agent’s Commissions . The Company acknowledges that it has retained Bradley Woods & Co. Ltd. to act as its managing Placement Agent (“ Placement Agent ”) and that Placement Agent may engage additional sub-agents that are FINRA member firms (“ Sub-Agents ”), to assist with the Company’s private placement. The Company shall pay to the Placement Agent (and/or their respective agents): (a) a fee in cash equal to a maximum of 8% of the gross cash proceeds to the Company resulting from the sale of certain of the Units in this Offering; and (b) a fee equal to a maximum of such number of shares and warrants as equals 7% of the shares of Common Stock (“ Placement Agent Shares ”) and 8% of the number of Warrants (“ Placement Agent Warrants ”) comprising the Units sold in the offering, which securities shall have the same terms and conditions as provided to the Purchasers (collectively, the “ Placement Agent Fees ”) and (c) a fee in cash of 1% of the gross offering by the Company and all other FINRA firms introduced in the offering, as a non-accountable expense allowance, but no higher than $5,000.

 

8.2            Legal Fees . The Company shall pay all legal fees of the Placement Agent in connection with this Agreement of $5,000 (of which $2,500 shall have been paid upon finalizing of the initial term sheet prior to commencement of the offering, and the balance, but not exceeding $5,000 in the aggregate, paid at the first closing) plus, if any, blue sky legal costs, printing, and filing fees. In addition, the Company shall reimburse Placement Agent’s hourly expenses for any subsequent closings after the first Closing, or for any material modifications of the Transaction Documents made at any time so long as previously agreed to in writing by the Company and the Placement Agent.

 

9.           MISCELLANEOUS.

 

9.1            Indemnification . Each Purchaser agrees to defend, indemnify and hold the Company harmless against any liability, costs or expenses arising as a result of any dissemination of any of the Securities by such Purchaser in violation of the Securities Act or applicable state securities law.

 

9.2            Governing Law . The validity and interpretation of this Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of New York. Each of the parties hereto and their assigns hereby consents to the exclusive jurisdiction and venue of the Courts of the State of New York, located in the City and County of New York and the United States District Court, Southern District, for the State of New York with respect to any matter relating to this Agreement and performance of the parties’ obligations hereunder, the documents and instruments executed and delivered concurrently herewith or pursuant hereto and performance of the parties’ obligations thereunder and each of the parties hereto hereby consents to the personal jurisdiction of such courts and shall subject itself to such personal jurisdiction. Any action, suit or proceeding relating to such matters shall be commenced, pursued, defended and resolved only in such courts and any appropriate appellate court having jurisdiction to hear an appeal from any judgment entered in such courts. The parties irrevocably waive the defense of an inconvenient forum to the maintenance of such suit or proceeding. Service of process in any action, suit or proceeding relating to such matters may be made and served within or outside the State of New York by registered or certified mail to the parties and their representatives at their respective addresses specified in Section 9.7, provided that a reasonable time, not less than thirty (30) days, is allowed for response. Service of process may also be made in such other manner as may be permissible under the applicable court rules. THE PARTIES HERETO WAIVE TRIAL BY JURY.

 

9.3            Successors and Assigns . Except as otherwise expressly provided herein, the provisions hereof shall inure to the benefit of, and be binding upon, the successors, assigns, heirs, executors, and administrators of the parties hereto.

 

23
 

 

9.4            Entire Agreement . This Agreement and the Exhibits hereto and thereto, and the other documents delivered pursuant hereto and thereto, constitute the full and entire understanding and agreement among the parties with regard to the subjects hereof and no party shall be liable or bound to any other party in any manner by any representations, warranties, covenants, or agreements except as specifically set forth herein or therein. Nothing in this Agreement, express or implied, is intended to confer upon any party, other than the parties hereto and their respective successors and assigns, any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided herein.

 

9.5            Severability . In case any provision of this Agreement shall be invalid, illegal, or unenforceable, it shall to the extent practicable, be modified so as to make it valid, legal and enforceable and to retain as nearly as practicable the intent of the parties, and the validity, legality, and enforceability of the remaining provisions shall not in any way be affected or impaired thereby.

 

9.6            Amendment and Waiver . Except as otherwise provided herein, any term of this Agreement may be amended, and the observance of any term of this Agreement may be waived (either generally or in a particular instance, either retroactively or prospectively, and either for a specified period of time or indefinitely), with the written consent of the Company and a majority of the Purchasers, or, to the extent such amendment affects only one Purchaser, by the Company and such Purchaser. Any amendment or waiver effected in accordance with this Section shall be binding upon each future holder of any security purchased under this Agreement (including securities into which such securities have been converted) and the Company.

 

9.7            Notices . All notices and other communications required or permitted hereunder shall be in writing and shall be effective when delivered personally, or sent by telex or telecopier (with receipt confirmed), provided that a copy is mailed by registered mail, return receipt requested, or when received by the addressee, if sent by Express Mail, Federal Express or other express delivery service (receipt requested) in each case to the appropriate address set forth below:

 

If to the Company: Vystar Corporation
  3235 Satellite Blvd
  Building 400
  Suite 490
  Facsimile:  (770) 965-0162
  Attn:  William Doyle, Chairman & CEO
   
With a copy to: Greenberg Traurig, LLP
  Suite 2500
  3333 Piedmont Rd.
  Atlanta, GA  30305
  Facsimile: 678-553-2431
  Email: baxterg@gtlaw.com
  Attn:  Gerald L. Baxter, Esq.
   
If to the Purchaser: At the address set forth on the Purchaser’s Signature Page
   
With a copy to: Bradley Woods & Co. Ltd. 
  805 Third Ave., 18th Fl.
  New York, NY 10022
  Facsimile:  (212) 758-4967
  Attention:  Dan Ripp

 

24
 

 

With a copy to: Levy International Law, LLC
  590 Madison Avenue, Suite 2100
  New York, New York 10022
  Facsimile:  (646) 219-1574
  Attention:  Ron Levy, Esq.

 

9.8            Faxes, Electronic Mail and Counterparts . This Agreement may be executed in one or more counterparts. Delivery of an executed counterpart of the Agreement or any exhibit attached hereto by facsimile transmission or electronic mail (any such delivery, an “ Electronic Delivery ”), shall be treated in all manner and respects as an original agreement or instrument and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person. At the request of any party hereto, each other party hereto shall re-execute original forms hereof and deliver them in person to all other parties. No party hereto shall raise the use of Electronic Delivery to deliver a signature or the fact that any signature or agreement or instrument was transmitted or communicated through the use of Electronic Delivery as a defense to the formation of a contract, and each such party forever waives any such defense, except to the extent such defense related to lack of authenticity.

 

9.9            Consent of Purchasers . Each Purchaser hereby irrevocably consents to the appointment of Bradley Woods & Co. Ltd. and/or its affiliates as their representative (the “ Representative ”) for the purposes of appointing a director designee. As used in the Agreement, “consent of the Purchasers” or similar language means the consent of the Representative. The appointment of the Representative is coupled with an interest and all authority hereby conferred shall be irrevocable and shall not be terminated by any or all of the Purchasers without the consent of the Company, which consent may be withheld for any reason, and the Representative is hereby authorized and directed to perform and consummate on behalf of the Purchasers. The Purchasers hereby hold harmless Bradley Woods & Co. Ltd. from any and all liabilities or claims or losses other than intentional malfeasance.

 

9.10          Titles and Subtitles . The titles of the paragraphs and subparagraphs of this Agreement are for convenience of reference only and are not to be considered in construing this Agreement.

 

9.11          Further Assurances . At any time and from time to time after the Closing, upon reasonable request of the other, each party shall do, execute, acknowledge and deliver such further acts, assignments, transfers, conveyances and assurances as may be reasonably required for the more complete consummation of the transactions contemplated herein.

 

9.12          Legal Fees . In the event any suit or other legal proceeding is brought for the enforcement of any of the provisions of this Agreement, the parties hereto agree that the prevailing party or parties shall be entitled to recover from the other party or parties upon final judgment on the merits reasonable attorneys’ fees, including attorneys’ fees for any appeal, and costs incurred in bringing such suit or proceeding.

 

APPLICABLE ONLY IN THE EVENT ANY UNITS ARE SOLD TO FLORIDA RESIDENTS - FLORIDA LAW PROVIDES THAT WHEN SALES ARE MADE TO FIVE OR MORE PERSONS IN FLORIDA, ANY SALE MADE IN FLORIDA IS VOIDABLE BY THE PURCHASER WITHIN THREE DAYS AFTER THE FIRST TENDER OF CONSIDERATION IS MADE BY SUCH PURCHASER TO THE COMPANY, AN AGENT OF THE COMPANY OR AN AUTHORIZED ESCROW AGENT OR WITHIN THREE DAYS AFTER THE AVAILABILITY OF THAT PRIVILEGE IS COMMUNICATED TO SUCH PURCHASER, WHICHEVER OCCURS LATER. THIS SALE IS BEING MADE IN FLORIDA. PAYMENTS FOR TERMINATED SUBSCRIPTIONS VOIDED BY PURCHASERS AS PROVIDED FOR IN THIS PARAGRAPH WILL BE PROMPTLY REFUNDED WITHOUT INTEREST. NOTICE SHOULD BE GIVEN TO THE COMPANY AT THE ADDRESS SPECIFIED HEREIN.

 

25
 

 

[Counterpart Signature Page To Securities Purchase Agreement of

Vystar Corporation]

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date set forth on the Purchase Signature Page hereto. 

 

  PURCHASER
   
  (By Counterpart Form - See Purchaser Signature
  Pages following the Questionnaire)
   
  COMPANY
   
  VYSTAR CORPORATION
   
   
  (By Execution of Acceptance Page following Certificate of Signatory)

 

26
 

 

PURCHASER SIGNATURE PAGES

 

The undersigned Purchaser has read the Securities Purchase Agreement of Vystar Corporation, a Georgia corporation dated as of May __, 2012, and acknowledges that the completion of this Questionnaire and the execution of the Purchaser Signature Page that follows shall constitute the undersigned’s execution of such Agreement. This Questionnaire is and shall remain part of the Agreement. All capitalized terms used herein shall be as defined in such Agreement 

 

I hereby subscribe for ____ Unit(s), at a Purchase Price of $25,000 per Unit, each Unit comprised of 100,000 Shares of Common Stock of the Company, Warrants to purchase 100,000 shares of Common Stock at an exercise price of $0.35 per share, for an aggregate Purchase Price of $__________________.  

 

I am a resident of the State(s) or Country of __________________ and ___________________.

 

 

 

Please print above the exact name(s) in which the Shares and Warrants are to be held  

 

My address is:  
   
   
   
   
   
My phone number is:  

 

[Continued]

 

SP- 1
 

 

ACCREDITED INVESTOR QUESTIONNAIRE

Vystar Corporation Offering of Units

 

I acknowledge that the offering of the Units is subject to the Federal securities laws of the United States and state securities laws of those states in which the Units are offered, and that, pursuant to the U.S. Federal securities laws and state securities laws, the Units may be purchased by persons who come within the definition of an “ Accredited Investor ” as that term is defined in Rule 501(a) of Regulation D promulgated under the Securities Act (“ Regulation D ”).

 

By initialing one of the categories below, I represent and warrant that I come within the category so initialed and have truthfully set forth the factual basis or reason I come within that category. All information in response to this paragraph will be kept strictly confidential. I agree to furnish any additional information that the Company deems necessary in order to verify the answers set forth below.

 

NOTE: You must initial at least ONE category.

 

Individual Purchaser:

(A Purchaser who is an individual may initial either Category I, II, or III)

 

Category I ______ I am a director or executive officer of the Company.
     
Category II ______  I am an individual (not a partnership, corporation, etc.) whose individual net worth, or joint net worth with my spouse, presently exceeds $1,000,000.*
     
    Explanation. In calculation of net worth, you may include equity in personal property and real estate other than your principal residence , including cash, short term investments, stocks and securities. Equity in personal property and real estate should be based on the fair market value of such property less debt secured by such property.
     
Category III ______  I am an individual (not a partnership, corporation, etc.) who had an individual income in excess of $200,000 in 2010 and 2011, or joint income with my spouse in excess of $300,000 in 2010 and 2011, and I have a reasonable expectation of reaching the same income level in 2012.**

 ____________________

* For purposes of this Accredited Investor Questionnaire, “ net worth ” means the excess of total assets at fair market value, including cash, stock, securities, personal property and real estate (other than your primary residence), over total liabilities (other than a mortgage or other debt secured by your primary residence). In the event that the amount of any mortgage or other indebtedness secured by your primary residence exceeds the fair market value of the residence, that excess liability should also be deducted from your net worth. Any mortgage or indebtedness secured by your primary residence incurred within 60 days before the time of the sale of the securities offered hereunder, other than as a result of the acquisition of the primary residence, shall also be deducted from your net worth. 

 

SP- 2
 

  

** For purposes of this Accredited Investor Questionnaire, individual income means adjusted gross income, as reported for federal income tax purposes, less any income attributable to a spouse or to property owned by a spouse, increased by the following amounts (but not including any amounts attributable to a spouse or to property owned by a spouse): (i) the amount of any tax-exempt interest income under Section 103 of the Internal Revenue Code of 1986, as amended (the “ Code ”), received; (ii) the amount of losses claimed as a limited partner in a limited partnership as reported on Schedule E of Form 1040; (iii) any deduction claimed for depletion under Section 611 et seq. of the Code; (iv) amounts contributed to an Individual Retirement Account (as defined in the Code) or Keogh retirement plan; (v) alimony paid;(vi) any elective contributions to a cash or deferred arrangement under Section 401(k) of the Code; and (vii) for applicable taxable years, any amount by which income from long-term capital gains has been reduced in arriving at adjusted gross income pursuant to the provisions of Section 1202 of the Code.

 

Entity Purchasers:

(A Purchaser which is a corporation, limited liability company, partnership, trust, or other entity may initial either Category IV, V, VI, VII or VIII)

 

Category IV ______  The Purchaser is an entity in which all of the equity owners are “ Accredited Investors ” as defined in Rule 501(a) of Regulation D. If relying upon this category alone, each equity owner must complete a separate copy of this Agreement.
     
     
     
     
     
     
    (describe entity)
     
Category V ______  The Purchaser is a trust, with total assets in excess of $5,000,000, not formed for the specific purpose of acquiring the Units offered, whose purchase is directed by a “ Sophisticated Person ” as described in Rule 506(b)(2)(ii) of Regulation D.
     
Category VI ______  The Purchaser is an organization described in Section 501(c)(3) of the Internal Revenue Code, corporation, Massachusetts or similar business trust, or partnership, not formed for the specific purpose of acquiring the Units, with total assets in excess of $5,000,000. 
     
     
     
     
     
     
    (describe entity)
     
Category VII ______  The Purchaser is a private business development company as defined in Section 202(a)(22) of the Investment Advisers Act of 1940. 
     
     
     
     
     
     
    (describe entity)

 

SP- 3
 

 

Category VIII  ______  Any bank as defined in section 3(a)(2) of the Securities Act of 1933, as amended (“ Act ”), or any savings and loan association or other institution as defined in section 3(a)(5)(A) of the Act whether acting in its individual or fiduciary capacity; any broker or dealer registered pursuant to section 15 of the Securities Exchange Act of 1934; any insurance company as defined in section 2(a)(13) of the Act; any investment company registered under the Investment Company Act of 1940 or a business development company as defined in section 2(a)(48) of that Act; any Small Business Investment Company licensed by the U.S. Small Business Administration under section 301(c) or (d) of the Small Business Investment Act of 1958; any plan established and maintained by a state, its political subdivisions, or any agency or instrumentality of a state or its political subdivisions, for the benefit of its employees, if such plan has total assets in excess of $5,000,000; any employee benefit plan within the meaning of the Employee Retirement Income Security Act of 1974 if the investment decision is made by a plan fiduciary, as defined in section 3(21) of such act, which is either a bank, savings and loan association, insurance company, or registered investment adviser, or if the employee benefit plan has total assets in excess of $5,000,000 or, if a self-directed plan, with investment decisions made solely by persons that are accredited investors;
     
     
     
     
     
     
    (describe entity)

 

Executed this _____ day of _________, 2012 at ____________________, ________________.

 

[Continued]

  

SP-4
 

  

REGULATION S CERTIFICATION

(For Non “U.S. Person” Individual or Entity Purchasers Only)

 

This Regulation S Certification (“ Certification ”) is being delivered in connection with the Securities Purchase Agreement dated May __, 2012 (the “ Agreement ”), by and between Vystar Corporation, a Georgia corporation (the “ Company ”), and each of the purchasers who execute the Purchaser Signature Page thereto (the “ Purchaser ”), and may be relied upon by the Company, its transfer agent and its counsel in connection with the transactions contemplated by the Agreement and the issuance of Units contemplated by the Agreement. The undersigned Purchaser, being a party to the Agreement hereby certifies that the following statements are true, correct, and complete as of the date of this Certification. Capitalized terms used and not defined herein shall have the meanings assigned to them in the Agreement.

 

1.          Purchaser is familiar with Regulation S (“ Regulation S ”) promulgated by the U.S. Securities and Exchange Commission (the “ SEC ”) under the U.S. Securities Act of 1933, as amended (the “ Securities Act ”).

 

2.          Purchaser is a not a “U.S. Person,” as defined in Regulation S and as set forth in the Agreement .

 

3.          Purchaser and each Unit Holder (as defined below) understand and acknowledge that (A) the Securities have not been registered under the Securities Act, are being sold in reliance upon an exemption from registration afforded by Regulation S; and that such Securities have not been registered with any state securities commission or authority; (B) pursuant to the requirements of Regulation S, the Securities may not be transferred, sold or otherwise exchanged unless in compliance with the provisions of Regulation S and/or pursuant to registration under the Securities Act, or pursuant to another available exemption thereunder; (C) the Company is under no obligation to register the Securities under the Securities Act or any state securities law, or to take any action to make any exemption from any such registration provisions available; and (D) the Company will refuse to register any transfer of Securities not made in accordance with the provisions of Regulation S, and/or pursuant to registration under the Securities Act of pursuant to another available exemption thereunder.

 

4.          Purchaser has requested that certificates representing the Securities be issued in the name of certain clients or customers of Purchaser who have provided funds for the acquisition of the Securities (such persons and entities referred to as “ Unit Holders ”). No Unit Holder is a “U.S. Person” as defined in Regulation S. Neither Purchaser nor any Unit Holder is acquiring the Securities for the account of any U.S. Person.

 

5.          Neither Purchaser nor any Unit Holder was formed specifically for the purpose of acquiring the Securities pursuant to the Agreement.

 

6.          The offer leading to the issuance of the Securities, to any transfer of Securities to the Unit Holders, and to the issuance of certificates to the Unit Holders, was made in an “offshore transaction” as defined in Regulation S. For purposes of Regulation S, Purchaser understands that an “offshore transaction” as defined under Regulation S is any offer or sale not made to a person in the United States and either (A) at the time the buy order is originated, the purchaser is outside the United States, or the seller or any person acting on his/her behalf reasonably believes that the purchaser is outside the United States; or (B) for purposes of (1) Rule 903 of Regulation S, the transaction is executed in, or on or through a physical trading floor of an established foreign exchange that is located outside the United States or (2) Rule 904 of Regulation S, the transaction is executed in, on or through the facilities of a designated offshore securities market, and neither the seller nor any person acting on its behalf knows that the transaction has been prearranged with a buyer in the U.S.

 

SP- 5
 

 

7.          Neither Purchaser, nor any affiliate or any person or entity acting on Purchaser’s behalf, nor any Unit Holder, has made or is aware of any “directed selling efforts” in the United States, which is defined in Regulation S to be any activity undertaken for the purpose of, or that could reasonably be expected to have the effect of, conditioning the market in the United States for any of the Securities.

 

8.          Purchaser understands that the Company is the issuer of the Securities which are the subject of the Agreement, and that, for purpose of Regulation S, a “distributor” is any underwriter, dealer or other person who participates, pursuant to a contractual arrangement, in the distribution of securities offered or sold in reliance on Regulation S and that an “affiliate” is any partner, officer, director or any person directly or indirectly controlling, controlled by or under common control with any person in question. Purchaser agrees that Purchaser will not, during the Restricted Period set forth under Rule 903(b)(iii)(A), act as a distributor, either directly or through any affiliate, nor shall he/she sell, transfer, hypothecate or otherwise convey the Securities other than to a non-U.S. Person.

 

Resale Restrictions

 

9.          Purchaser is purchasing the Units for its own account and risk and not for the account or benefit of a U.S. Person (as defined in Regulation S). Purchaser understands, acknowledges and agrees that he/she must bear the economic risk of an investment in the Securities for an indefinite period of time and that prior to any such offer or sale, the Company may require, as a condition to effecting a transfer of the Securities, an opinion of counsel, acceptable to the Company, as to the registration or exemption therefrom under the Securities Act and any state securities acts, if applicable.

 

10.         Purchaser will, during and after the expiration of the distribution compliance period, as set forth under Regulation S Rule 903(b)(3)(iii)(A), offer, sell, pledge or otherwise transfer the Securities only in accordance with Regulation S, or pursuant to an available exemption under the Securities Act. The issuance of the Securities pursuant to the Agreement has neither been pre-arranged with a purchaser who is in the U.S. or who is a U.S. Person, nor is it part of a plan or scheme to evade the registration provisions of the United States federal securities laws. During such distribution compliance period, Purchaser will not engage in hedging transactions with regard to the common stock of the Company, unless in compliance with the Securities Act.

 

Legends

 

11.         Purchaser acknowledges, on behalf of Purchaser and the Unit Holders, that substantially the following legend may appear on any certificates that may be issued in respect of the Securities:

 

THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE BEEN OFFERED AND SOLD IN AN “OFFSHORE TRANSACTION” IN RELIANCE UPON REGULATION S AS PROMULGATED BY THE SECURITIES AND EXCHANGE COMMISSION. ACCORDINGLY, THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE “SECURITIES ACT”) AND MAY NOT BE TRANSFERRED OTHER THAN IN ACCORDANCE WITH REGULATION S, PURSUANT TO REGISTRATION UNDER THE SECURITIES ACT, OR PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT, THE AVAILABILITY OF WHICH IS TO BE ESTABLISHED TO THE SATISFACTION OF THE COMPANY. THE SECURITIES REPRESENTED BY THIS CERTIFICATE CANNOT BE THE SUBJECT OF HEDGING TRANSACTIONS UNLESS SUCH TRANSACTIONS ARE CONDUCTED IN COMPLIANCE WITH THE SECURITIES ACT.

 

SP- 6
 

 

IN WITNESS WHEREOF, the undersigned has executed this Regulation S Certification as of the date set forth below. 

 

PURCHASER:  

 

NAME:    
     
By:    
     
Title:    
     
DATED:    

 

[ Signature Page to Regulation S Certification ]

 

[Signature Pages Continue]

 

SP- 7
 

 

PURCHASER SIGNATURE PAGE

(For Individual Purchasers)

 

This Securities Purchase Agreement of Vystar Corporation (including the Questionnaire) is hereby executed and entered into by the below Purchaser.

 

   
No. of Units: __________(@$25,000 per Unit)                                                                        
  Signature (Individual)
No. of Shares/Warrants: _______________  
                                                                         
Purchase Price $_____________ Name (Print)
   
                                                                         
  Street address
   
                                                                         
  City, State, Zip Code & Country
   
                                                                         
  Tax Identification or Social Security Number
   
  (            )                                                         
  Telephone Number
   
  (            )                                                         
  Facsimile Number
   
  Address to Which Correspondence Should Be Directed (if different from above)
   
  ____________________________________
  c/o Name
  ____________________________________
  Street Address
      
  ____________________________________
  City, State, Zip Code & Country
   
  (______)____________________________
  Telephone Number
   
  (______)____________________________
  Facsimile Number

 

SP- 8
 

 

PURCHASER SIGNATURE PAGE

(for Corporation, Partnership, Trust or Other Entities)

 

This Securities Purchase Agreement of Vystar Corporation (including the Questionnaire) is hereby executed and entered into by the below Purchaser:

 

  ____________________________________
No. of Units: __________(@$25,000 per Unit) Name of Entity
   
No. of Shares/Warrants: _______________                                                                        ____
  Type of Entity (i.e., corporation, partnership, etc.)
Purchase Price $_____________  
   
                                                                         __
  Tax Identification or Social Security Number
   
                                                                         
  State of Formation of Entity
   
                                                                         
  Name of Signatory Typed or Printed
   
  Its: _________________________________
              Title
   
  Address to Which Correspondence Should Be Directed (if different from above)
   
  ____________________________________
  c/o Name
  ____________________________________
  Street Address
      
  ____________________________________
  City, State,  Zip Code & Country
   
  (______)____________________________
  Telephone Number
   
  (______)____________________________
  Facsimile Number

 

*If Units are being subscribed for by an entity, the Certificate of Signatory that follows must also be completed.

 

SP- 9
 

 

CERTIFICATE OF SIGNATORY

 

(To be completed if Units are being subscribed for by an entity)

 

 

I,__________________________________, am the ___________________________ of

 

_________________________________________________________________(the “ Entity ”).

 

I certify that I am empowered and duly authorized by the Entity to execute and carry out the terms of the Securities Purchase Agreement and to purchase and hold the Shares and Warrants that comprise the Units. The Securities Purchase Agreement has been duly and validly executed on behalf of the Entity and constitutes a legal and binding obligation of the Entity.

 

IN WITNESS WHEREOF, I have hereto set my hand this ______ day of _________, 2012.

  

   
  Signature

 

SP- 10
 

 

ACCEPTANCE PAGE TO SECURITIES PURCHASE AGREEMENT OF

VYSTAR CORPORATION

 

The foregoing subscriptions for ________ Units (with 100,000 Shares and Warrants per Unit), for an aggregate purchase price of $___________ at a Purchase Price of $25,000 per Unit, in accordance with the foregoing Securities Purchase Agreement, AGREED AND ACCEPTED; provided, however , that the Company may accept additional subscriptions from time to time without consent of Purchasers until the maximum offering amount (plus the over-allotment option, if any) are accepted and Closed upon, in accordance with this Agreement:

 

VYSTAR CORPORATION  
   
By:    
Name:   
Title: Chief Executive Officer  

 

Date: ___________________

 

SP- 11
 

 

 

COMPANY DISCLOSURE SCHEDULE

 

Capitalized terms not otherwise defined in this Company Disclosure Schedule shall have the same meaning as in the Agreement.

 

The disclosure of any matter in this Company Disclosure Schedule should not be construed as indicating that such matter is necessarily required to be disclosed in order for any representation or warranty in the Agreement to be true and correct in all material respects. Any description of any document included in this Company Disclosure Schedule is qualified in all respects by reference to such document.

 

Schedules
 

 

SCHEDULE 3.2

 

OUTSTANDING NOTES, CONVERTIBLE DEBT, DERIVATIVES, AND NOTES OF THE COMPANY

 

 

 
 

 

SCHEDULE 3.2 (CONT’D)

 

OUTSTANDING NOTES, CONVERTIBLE DEBT, DERIVATIVES, AND NOTES OF THE COMPANY

 

 
 

 

SCHEDULE 3.6

 

MATERIAL ADVERSE CHANGE

 

None.

 

 
 

 

SCHEDULE 3.11

 

INTELLECTUAL PROPERTY

 

None.

 

 
 

 

SCHEDULE 3.13

 

LITIGATION

 

None.

 

 
 

 

EXHIBIT A

 

Form of Common Stock Purchase Warrant

 

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE

SARBANES-OXLEY ACT OF 2002

 

I, William R. Doyle, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Vystar Corporation (the “Company”);

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;

 

4. The Company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and we have:

 

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision to ensure that material information relating to the Company is made known to us particularly during the period in which this report is being prepared;

 

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c) Evaluated the effectiveness of the Company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d) Disclosed in this report any change in the Company’s internal control over financial reporting that occurred during the Company’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

5. The Company’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company’s auditors and the audit committee of the Company’s board of directors (or persons performing the equivalent functions):

 

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and

 

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting.

 

Date: August 10, 2012 By:  /s/ William R. Doyle
   

Chairman, President and Chief Executive

Officer

 

 
 

 

 

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE

SARBANES-OXLEY ACT OF 2002

 

I. Linda S. Hammock, certify that:

 

1. I have reviewed this Quarterly Report on Form 10-Q of Vystar Corporation (the “Company”);

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report;

 

4. The Company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and we have:

 

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision to ensure that material information relating to the Company is made known to us particularly during the period in which this report is being prepared;

 

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c) Evaluated the effectiveness of the Company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d) Disclosed in this report any change in the Company’s internal control over financial reporting that occurred during the Company’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

5. The Company’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company’s auditors and the audit committee of the Company’s board of directors (or persons performing the equivalent functions):

 

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and

 

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting.

 

Date: August 10, 2012 By:  /s/ Linda S. Hammock
    Acting Chief Financial Officer

 

 
 

 

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Vystar Corporation (the “Company”) on Form 10-Q for the quarter ended June 30, 2012 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, William R. Doyle, Chairman, President and Chief Executive Officer of the Company, and Linda S. Hammock, Acting Chief Financial Officer of the Company, each do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of our knowledge:

 

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

/s/ William R. Doyle  
William R. Doyle  
Chairman, President and Chief Executive Officer  
August 10, 2012  
   
/s/ Linda S. Hammock  
Linda S. Hammock  
Acting Chief Financial Officer  
August 10, 2012  

 

A signed original of this written statement required by Section 906 has been provided to Vystar Corporation and will be retained by Vystar Corporation and furnished to the Securities and Exchange Commission or its staff upon request.

 

The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of Vystar Corporation, whether made before or after the date hereof, regardless of any general incorporation language in such filing.